WO2001072717A1 - 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases - Google Patents

4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases Download PDF

Info

Publication number
WO2001072717A1
WO2001072717A1 PCT/GB2001/001264 GB0101264W WO0172717A1 WO 2001072717 A1 WO2001072717 A1 WO 2001072717A1 GB 0101264 W GB0101264 W GB 0101264W WO 0172717 A1 WO0172717 A1 WO 0172717A1
Authority
WO
WIPO (PCT)
Prior art keywords
sulphamoyl
alkyl
formula
compound
amino
Prior art date
Application number
PCT/GB2001/001264
Other languages
French (fr)
Inventor
Andrew Peter Thomas
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE60113080T priority Critical patent/DE60113080T2/en
Priority to AT01914026T priority patent/ATE303366T1/en
Priority to JP2001570630A priority patent/JP2003528861A/en
Priority to US10/239,790 priority patent/US6906065B2/en
Application filed by Astrazeneca Ab, Astrazeneca Uk Limited filed Critical Astrazeneca Ab
Priority to EP01914026A priority patent/EP1268445B1/en
Priority to AU3941401A priority patent/AU3941401A/en
Priority to MXPA02009255A priority patent/MXPA02009255A/en
Priority to NZ521032A priority patent/NZ521032A/en
Priority to IL15139201A priority patent/IL151392A0/en
Priority to AU2001239414A priority patent/AU2001239414B2/en
Priority to BR0109577-3A priority patent/BR0109577A/en
Priority to CA002399864A priority patent/CA2399864A1/en
Publication of WO2001072717A1 publication Critical patent/WO2001072717A1/en
Priority to IL151392A priority patent/IL151392A/en
Priority to NO20024644A priority patent/NO324228B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the invention relates to pyrimidine derivatives, or pharmaceutically acceptable salts or in vivo hydrolysable esters thereof, which possess cell-cycle inhibitory activity and are accordingly useful for their anti-cell-proliferation (such as anti-cancer) activity and are therefore useful in methods of treatment of the human or animal body.
  • the invention also relates to processes for the manufacture of said pyrimidine derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cell-proliferation effect in a warm-blooded animal such as man.
  • a family of intracellular proteins called cyclins play a central role in the cell cycle.
  • Cyclins bind to cyclin-dependent serine/threonine kinases (CDKs) and this association is essential for CDK (such as CDK1, CDK2, CDK4 and/or CDK6) activity within the cell.
  • CDKs cyclin-dependent serine/threonine kinases
  • CDKs appear to be downstream of a number of oncogene signalling pathways.
  • Disregulation of CDK activity by upregulation of cyclins and/or deletion of endogenous inhibitors appears to be an important axis between mitogenic signalling pathways and proliferation of tumour cells.
  • an inhibitor of cell cycle kinases particularly inhibitors of CDK2, CDK4 and/or CDK6 (which operate at the S-phase, Gl-S and Gl-S phase respectively) should be of value as a selective inhibitor of cell proliferation, such as growth of mammalian cancer cells.
  • the present invention is based on the discovery that certain pyrimidine compounds surprisingly inhibit the effects of cell cycle kinases showing selectivity for CDK2, CDK4 and CDK6, and thus possess anti-cell-proliferation properties.
  • Such properties are expected to be of value in the treatment of disease states associated with aberrant cell cycles and cell proliferation such as cancers (solid tumours and leukemias), fibroproliferative and differentiative disorders , psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation.
  • the present invention provides a compound of formula (I):
  • R 1 is halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, C, .6 alkyl, C 2.6 alkenyl or C 2-6 alkynyl; p is 0-4; wherein the values of R 1 may be the same or different;
  • R 2 is sulphamoyl or a group B-E-;
  • B is selected from C ⁇ alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3 . 8 cycloalkyl, C 3.g cycloalkylC,. 6 alkyl, phenyl, a heterocyclic group, phenylC ⁇ alkyl or (heterocyclic group)C 1 . 6 alkyl; wherein said C h alky!, C 2 . 6 alkenyl, C 2.6 alkynyl, C 3.g cycloalkyl, C 3.8 cycloalkylC 1 . 6 alkyl, phenyl, heterocyclic group, phenylC j. galkyl or (heterocyclic group)C ! .
  • 6 alkyl are optionally substituted on carbon by one or more D; and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from G;
  • E is -C(O)-, -N(R a )C(O)-, -C(O)N(R a )-, -S(O) r -, -SO 2 N(R a )- or -N(R a )SO 2 -; wherein R a is hydrogen or .galkyl optionally substituted by one or more D and r is 1-2;
  • D is independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C 1-6 alkyl, C 2.6 alkenyl, C 2 . 6 alkynyl, NN-(C 1 . 6 alkyl) 2 amino, C 1 . 6 alkanoylamino, NN-(C 1 . 6 alkyl) 2 carbamoyl, C 1 . 6 alkylS(O) a wherein a is 0 to 2, C L galkoxycarbonyl, and NN-(C,.
  • alkyl includes both straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl” are specific for the straight chain version only.
  • C ⁇ . 6 alkyl includes C M alkyl, C ⁇ alkyl, propyl, isopropyl and t-butyl.
  • references to individual alkyl groups such as 'propyl' are specific for the straight chained version only and references to individual branched chain alkyl groups such as 'isopropyl' are specific for the branched chain version only.
  • a similar convention applies to other radicals, for example "phenylC ⁇ _ 6 alkyl” includes phenylC 1 . 4 alkyl, benzyl, 1-phenylethyl and 2-phenylethyl.
  • halo refers to fluoro, chloro, bromo and iodo.
  • a “heterocyclic group” is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 4-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH 2 - group can optionally be replaced by a -C(O)-, a ring nitrogen atom may optionally bear a C ⁇ aHcyl group and form a quaternary compound or a ring nitrogen and/or sulphur atom may be optionally oxidised to form the N-oxide and or the S-oxides.
  • heterocyclic group examples and suitable values of the term "heterocyclic group" are morpholino, piperidyl, pyridyl, pyranyl, pyrrolyl, isothiazolyl, indolyl, quinolyl, thienyl, 1,3-benzodioxolyl, thiadiazolyl, piperazinyl, thiazolidinyl, pyrrolidinyl, thiomo holino, pyrrolinyl, homopiperazinyl, 3,5- dioxapiperidinyl, tetrahydropyranyl, imidazolyl, pyrimidyl, pyrazinyl, pyridazinyl, isoxazolyl, N-methylpyrrolyl, 4-pyridone, 1-isoquinolone, 2-pyrrolidone, 4-thiazolidone, pyridine-N-oxide and quinoline-N-oxide.
  • a “heterocyclic group” is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, it may, unless otherwise specified, be carbon or nitrogen linked, a -CH 2 - group can optionally be replaced by a -C(O)-and a ring sulphur atom may be optionally oxidised to form the S-oxides. More preferably a "heterocyclic group” is tetrahydrofuryl, pyridyl, pyrrolidinonyl, morpholino, imidazolyl, piperidinyl or pyrrolidinyl.
  • C,. 6 alkanoyloxy is acetoxy.
  • C ⁇ . 6 alkoxycarbonyl include C M alkoxycarbonyl, methoxycarbonyl, ethoxycarbonyl, n- and t-butoxycarbonyl.
  • Examples of “C ⁇ alkoxy” include methoxy, ethoxy and propoxy.
  • Examples of “C ⁇ alkanoylamino” include formamido, acetamido and propionylamino.
  • Examples of "C 1 . 6 alkylS(O) a wherein a is 0 to 2” include Cj.
  • alkylsulphonyl methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl.
  • Examples of "C 1 . 6 alkylS(O) r wherein r is 1 to 2" include methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl.
  • Examples of "C ⁇ alkanoyl” include C M alkanoyl, propionyl and acetyl.
  • N-C ⁇ alkylamino include methylamino and ethylamino. Examples of "NN-(C,.
  • Examples of "C 2 . 6 alkyl) 2 amino" include di-N-methylamino, di-(N-ethyl)amino and N-ethyl-N-methylamino.
  • Examples of “C 2 . 6 alkenyl” are vinyl, allyl and 1-propenyl.
  • Examples of "C 2-6 alkynyl” are ethynyl, 1-propynyl and 2-propynyl. Examples of are N-(methyl)sulphamoyl and N-(ethyl)sulphamoyl.
  • Examples of "N-(C 1 . 6 alkyl) 2 sulphamoyl” are N,N-(dimethyl)sulphamoyl and
  • N-(methyl)-N-(ethyl)sulphamoyl examples of “N-(C ⁇ . 6 alkyl)carbamoyl” are N-(C 1 . 4 alkyl)carbamoyl, methylaminocarbonyl and ethylaminocarbonyl. Examples of “N,N-(C 1 . 6 alkyl) 2 carbamoyl” are N,N-(C 1 . 4 alkyl) 2 carbamoyl, dimethylaminocarbonyl and methylethylaminocarbonyl. Examples of "C 3 .
  • cycloalkyl are cyclopropyl, cyclobutyl, cyclopropyl and cyclohexyl.
  • Examples of "(heterocyclic group)C,. 6 alkyl” include pyridylmethyl, 3-morpholinopropyl and 2-pyrimid-2-ylethyl.
  • Examples of "C 3 _ 8 cycloalkylC 1 . 6 alkyl” are cyclopropylethyl, cyclobutylmethyl, 2-cyclopropylpropyl and cyclohexylethyl.
  • a suitable pharmaceutically acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid.
  • a suitable pharmaceutically acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
  • an alkali metal salt for example a sodium or potassium salt
  • an alkaline earth metal salt for example a calcium or magnesium salt
  • an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation
  • a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxye
  • the compounds of the formula (I) may be administered in the form of a pro-drug which is broken down in the human or animal body to give a compound of the formula (I).
  • pro-drugs include in vivo hydrolysable esters of a compound of the formula (I).
  • An in vivo hydrolysable ester of a compound of the formula (I) containing carboxy or hydroxy group is, for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol.
  • Suitable pharmaceutically acceptable esters for carboxy include esters for example methoxymethyl, C ⁇ _ 6 alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C 3 .
  • alkyl esters for example 1-cyclohexylcarbonyloxyethyl
  • l,3-dioxolen-2-onylmethyl esters for example 5-methyl-l,3-dioxolen-2-onylmethyl
  • C ⁇ alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.
  • An in vivo hydrolysable ester of a compound of the formula (I) containing a hydroxy group includes inorganic esters such as phosphate esters and ⁇ -acyloxyalkyl ethers and related compounds which as a result of the in vivo hydrolysis of the ester breakdown to give the parent hydroxy group.
  • inorganic esters such as phosphate esters and ⁇ -acyloxyalkyl ethers and related compounds which as a result of the in vivo hydrolysis of the ester breakdown to give the parent hydroxy group.
  • -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy.
  • a selection of in vivo hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and N-(dialkylaminoethyl)-N-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl.
  • substituents on benzoyl include morpholino and piperazino linked from a ring nitrogen atom via a methylene group to the 3- or 4- position of the benzoyl ring.
  • Some compounds of the formula (I) may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such optical, diastereoisomers and geometric isomers that possess CDK inhibitory activity.
  • the invention relates to any and all tautomeric forms of the compounds of the formula (I) that possess CDK inhibitory activity.
  • R 1 , R 2 , p and q are as follows. Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.
  • R 1 is halo or C 1-2 alkyl.
  • R 1 is fluoro, chloro or methyl.
  • R 1 is fluoro or chloro.
  • R 1 is chloro
  • R 1 is meta or para to the amino group of the aniline in formula (I). More preferably R 1 is meta to the amino group of the aniline in formula (I).
  • p is 0-2; wherein the values of R 1 may be the same or different.
  • p is 0 or 1.
  • p is 0.
  • p is 1. In a further aspect of the invention preferably p is 2; wherein the values of R 1 may be the same or different.
  • R 2 is sulphamoyl or a group B-E-; wherein
  • B is selected from C ⁇ alkyl, C 2-6 alkenyl, C 3 . 8 cycloalkyl, C 3 . 8 cycloalkylC 1 . 6 alkyl, phenylC ⁇ . 6 alkyl or (heterocyclic group)C ⁇ . 6 alkyl; wherein said C ⁇ alkyl, C 2 . 6 alkenyl, C 3 . 8 cycloalkyl 3 C 3 . 8 cycloalkylC 1 . 6 alkyl, phenylC ⁇ . 6 alkyl or (heterocyclic are optionally substituted on carbon by one or more D; and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from G;
  • E is -N(R )SO 2 -; wherein R a is hydrogen; D is independently selected from halo, hydroxy, C 1-6 alkoxy or N- .gaiky amino,
  • G is C ⁇ alkyl. More preferably R 2 is sulphamoyl or a group B-E-; wherein B is optionally substituted by D and is selected from ethyl, propyl, pentyl, allyl, cyclopropyl, cyclobutyl, cyclopropylmethyl, benzyl, phenethyl, tetrahydrofurylmethyl, pyridylethyl, pyrrolidinonylpropyl, morpholinopropyl, imidazolylpropyl, piperidinylethyl, pyrrolidinylethyl (optionally substituted on the ring nitrogen by methyl), E is -NHSO 2 -;
  • D is independently selected from fluoro, hydroxy, methoxy, ethoxy, isopropoxy, isopropylamino and dimethylamino.
  • R 2 is selected from sulphamoyl, N-(cyclopropyhnethyl)sulphamoyl, N-(tetrahydrofur-2-ylmethyl)sulphamoyl, N-(2-methoxyethyl)sulphamoyl, N-(2-pyrid-2-ylethyl)sulphamoyl, N-(2-piperidin- 1 -ylethyl)sulphamoyl, N-[2-(l-methylpyrrolidin-2-yl)ethyl]sulphamoyl, N-(2-isopropylaminoethyl)sulphamoyl, N-(2,2,2-trifluoroethyl)sulphamoyl, N-(3-methoxypropyl)sulphamoyl, N-(3-ethoxypropyl)sulphamoyl, N-(3-isopropoxypropyl)sulphamoyl, N-(
  • R 2 is sulphamoyl or a group B-E-; wherein
  • B is selected from C 1-6 alkyl, C 2 . 6 alkenyl, C 3 . 8 cycloalkyl, C 3 . 8 cycloalkylC ⁇ . 6 alkyl, C 2 . 6 alkenyl, C 3 . 8 cycloalkyl, C 3 . 8 cycloalkylC ⁇ . 6 alkyl, phenylC ⁇ alkyl or (heterocyclic group)C 1-6 alkyl are optionally substituted on carbon by one or more D; and wherein if said heterocyclic group contains an - ⁇ H- moiety that nitrogen may be optionally substituted by a group selected from G;
  • E is - ⁇ (R a )SO 2 - or -N(R a )C(O)-; wherein R a is hydrogen; D is independently selected from halo, hydroxy, C ⁇ alkoxy or N-(C ⁇ . 6 alkyl)amino,
  • R 2 is sulphamoyl or a group B-E-; wherein
  • B is optionally substituted by D and is selected from ethyl, propyl, pentyl, 2,2-dimethylpropyl, allyl, cyclopropyl, cyclobutyl, cyclopropylmethyl, benzyl, phenethyl, tetrahydrofurylmethyl, pyridylethyl, pyrrolidinonylpropyl, morpholinopropyl, imidazolylpropyl, piperidinylethyl, pyrrolidinylethyl (optionally substituted on the ring nitrogen by methyl),
  • E is -NHSO 2 - or -N(R a )C(O)-;
  • D is independently selected from fluoro, hydroxy, methoxy, ethoxy, isopropoxy, isopropylamino and dimethylamino.
  • R 2 is selected from sulphamoyl, N-(cyclopropylmethyl)sulphamoyl, N-(tetrahydrofur-2-ylmethyl)sulphamoyl, N-(2-methoxyethyl)sulphamoyl, N-(2-pyrid-2-ylethyl)sulphamoyl, N-(2-piperidin- 1 -ylethyl)sulphamoyl, N-[2-(l -methylpyrrolidin-2-yl)ethyl]sulphamoyl, N-(2-isopropylaminoethyl)sulphamoyl, N-(2,2,2-trifluoroethyl)sulphamoyl, N-(2-dimethylaminoethyl)sulphamoyl, N-(3-methoxypropyl)sulphamoyl, N-(3-ethoxypropyl)sulphamoyl
  • R 2 is meta or para to the amino group of the aniline in formula (I).
  • R 2 is para to the amino group of the aniline in formula (I).
  • E is - ⁇ HSO 2 -.
  • E is -NHSO 2 - or -N(R a )C(O)-.
  • q is 0 or 1.
  • q is 0.
  • q is 1. In a further aspect of the invention preferably q is 2; wherein the values of R 2 may be the same or different.
  • p + q 1 or 2.
  • R 1 is halo or C 1 . 2 alkyl; p is 0-2; wherein the values of R 1 may be the same or different;
  • R 2 is sulphamoyl or a group B-E-; wherein B is selected from C ⁇ aHcyl, C 2-6 alkenyl, C 3 . 8 cycloalkyl, C 3 . 8 cycloalkylC 1 . 6 alkyl, phenylC 1-6 alkyl or (heterocyclic group)C 1 . 6 alkyl; wherein said C ⁇ aHcyl, C 2-6 alkenyl, C 3 . 8 cycloalkyl, C 3 . g cycloalkylC ⁇ . 6 alkyl, phenylC 1-6 alkyl or (heterocyclic group)C 1 . 6 alkyl are optionally substituted on carbon by one or more D; and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from G;
  • E is -N(R a )SO 2 -; wherein R a is hydrogen;
  • D is independently selected from halo, hydroxy, C 1-6 alkoxy or N-(C w alkyl)amino, NN-(C,. 6 alkyl) 2 amino;
  • R 1 is fluoro, chloro or methyl; p is O or l;
  • R 2 is sulphamoyl or a group B-E-;
  • B is optionally substituted by D and is selected from ethyl, propyl, pentyl, allyl, cyclopropyl, cyclobutyl, cyclopropylmethyl, benzyl, phenethyl, tetrahydrofurylmethyl, pyridylethyl, pyrrolidinonylpropyl, morpholinopropyl, imidazolylpropyl, piperidinylethyl, pyrrolidinylethyl (optionally substituted on the ring nitrogen by methyl),
  • R 2 is selected from sulphamoyl, N-(cyclopropylmethyl)sulphamoyl, N-(tetrahydrofur-2-ylmethyl)sulphamoyl, N-(2-methoxyethyl)sulphamoyl, N-(2-pyrid-2-ylethyl)sulphamoyl, N-(2-piperidin- 1 -ylethyl)sulphamoyl,
  • N-(3 -isopropylaminopropyl)sulphamoyl N-(propyl)sulphamoyl, N-(pentyl)sulphamoyl, N-(allyl)sulphamoyl, N-(cyclopropyl)sulphamoyl, N-(cyclobutyl)sulphamoyl, N-(3-methoxybenzyl)sulphamoyl, N-(4-fluorobenzyl)sulphamoyl, N-(phenethyl)sulphamoyl, N-(4-hydroxyphenethyl)sulphamoyl and N-(4-methoxyphenethyl)sulphamoyl; and q is l; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.
  • preferred compounds of the invention are any one of Examples 1-27 or a pharmaceutically acceptable salt or an in vivo hydrolysable esters thereof. In another aspect of the invention, preferred compounds of the invention are any one of Examples 1-31 or a pharmaceutically acceptable salt or an in vivo hydrolysable esters thereof.
  • preferred compounds of formula (I) are: 4-amino-5-cyano-2- ⁇ 4-[N-(2-methoxyethyl)sulphamoyl]anilino ⁇ pyrimidine; 4-amino-5-cyano-2- ⁇ 4-[N-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino ⁇ pyrimidine; 4-amino-5-cyano-2- ⁇ 4-[N-(4-fluorobenzyl)sulphamoyl]anilino ⁇ pyrimidine; 4-amino-5-cyano-2- ⁇ 4-[N-(3-methoxypropyl)sulphamoyl]anilino ⁇ pyrimidine; 4-amino-5-cyano-2- ⁇ 4-[N-(cyclopropyl)sulphamoyl]anilino ⁇ pyrimidine; 4-amino-5-cyano-2-[4-(N-allylsulphamoyl)anilidine; 4-amino-5-
  • Preferred aspects of the invention are those which relate to the compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • Another aspect of the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof which process (wherein R 1 , R 2 , p and q are, unless otherwise specified, as defined in formula (I)) comprises of: a) reaction of a pyrimidine of formula (II) :
  • L is a displaceable group, suitable values for L are for example, a halogeno or sulphonyloxy group, for example a chloro, bromo, methanesulphonyloxy or toluene-4-sulphonyloxy group.
  • X is a displaceable group
  • suitable values for L are for example, a halogeno group, for example a fluoro, chloro or bromo group.
  • X is fluoro.
  • Compounds of formula (V) and (VI) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.
  • a base for example an inorganic base such as caesium carbonate in the presence of an inert solvent such as toluene or tetrahydrofuran, or in the presence of an organic base such as excess (IX) and at a temperature in the range of 25 to 80°C.
  • aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group.
  • modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.
  • a suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl.
  • the deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • an acyl group such as a t-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate).
  • a suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.
  • a suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl.
  • the deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • a suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • a base such as sodium hydroxide
  • a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • the protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art. 5 As stated hereinbefore the compounds defined in the present invention possesses anti-cell-proliferation activity such as anti-cancer activity which is believed to arise from the
  • CDK inhibitory activity of the compound may be assessed, for example, using the procedure set out below:
  • HEPES is N-[2-Hydroxyethyl]piperazine-N-[2-ethanesulfonic acid]
  • DTT is Dithiothretiol
  • PMSF Phenylmethylsulfonyl fluoride
  • the compounds were tested in an in vitro kinase assay in 96 well format using 15 Scintillation Proximity Assay (SPA - obtained from Amersham) for measuring incorporation of [ ⁇ -33-P]-Adenosine Triphosphate into a test substrate (GST-Retinoblastoma protein; GST-
  • GST-Rb/ATP/ATP33 mixture (containing 0.5 ⁇ g GST-Rb and 0.2 ⁇ M ATP and 0.14 ⁇ Ci [ ⁇ -33-
  • the plates were sealed with Topseal-S plate sealers, left for two hours then spun at 30 2500rpm, 1124xg., for 5 minutes. The plates were read on a Topcount for 30 seconds per well.
  • the incubation buffer used to dilute the enzyme and substrate mixes contained 50mM HEPES pH7.5, lOmM MnCL . , ImM DTT, lOO ⁇ M Sodium vanadate, lOO ⁇ MNaF, lOmM Sodium Glycerophosphate, BSA (lmg/ml final). Test substrate In this assay only part of the retinoblastoma protein (Science 1987
  • the retinoblastoma 792-928 sequence so obtained was expressed in E.Coli (BL21 (DE3) pLysS cells ) using standard inducible expression techniques, and purified as follows. E.coli paste was resuspended in lOml/g of ⁇ ET ⁇ buffer (50mM Tris pH 7.5, 120mM ⁇ aCl, lmM EDTA, 0.5%v/v ⁇ P-40, ImM PMSF, lug/ml leupeptin, lug/ml aprotinin and lug/ml pepstatin) and sonicated for 2 x 45 seconds per 100ml homogenate.
  • ⁇ ET ⁇ buffer 50mM Tris pH 7.5, 120mM ⁇ aCl, lmM EDTA, 0.5%v/v ⁇ P-40, ImM PMSF, lug/ml leupeptin, lug/ml aprotinin and lug/ml pepstatin
  • CDK2 and Cyclin E were isolated by reverse transcriptase-PCR using HeLa cell and activated T cell mRNA as a template and cloned into the insect expression vector pNLl 393 (obtained from Invitrogen 1995 catalogue number: N1392-20). CDK2 and cyclin E were then dually expressed [using a standard virus
  • Example provides details of the production of Cyclin E/CDK2 in SF21 cells (in TC100 + 10% FBS(TCS) + 0.2% Pluronic) having dual infection MOI 3 for each virus of Cyclin E & CDK2.
  • 5 SF21 cells grown in a roller bottle culture to 2.33 x 10 6 cells/ml were used to inoculate
  • viruses were mixed together before addition to the cultures, and the cultures returned to the roller rig 28°C.
  • Sf21 cells were resuspended in lysis buffer (50mM Tris pH 8.2, lOmM MgCl 2 , ImM DTT, lOmM glycerophosphate, O.lmM sodium orthovanadate, O.lmM NaF, ImM PMSF, 20 lug/ml leupeptin and lug/ml aprotinin) and homogenised for 2 minutes in a 10ml Dounce homgeniser. After centrifugation, the supernatant was loaded onto a Poros HQ/M 1.4/100 anion exchange column (PE Biosystems, Hertford, UK).
  • lysis buffer 50mM Tris pH 8.2, lOmM MgCl 2 , ImM DTT, lOmM glycerophosphate, O.lmM sodium orthovanadate, O.lmM NaF, ImM PMSF, 20 lug/ml leupeptin and lug/ml aprotinin
  • Cdk2 and Cyclin E were coeluted at the beginning of a 0-1 M NaCl gradient (run in lysis buffer minus protease inhibitors) over 20 column volumes. Co-elution was checked by western blot using both anti-Cdk2 and anti- 25 Cyclin E antibodies (Santa Cruz Biotechnology, California, US).
  • CDK2 EMBL Accession No. X62071
  • Cyclin A or Cyclin E see EMBL Accession No. M73812
  • PCT International Publication No. WO99/21845 the relevant Biochemical & 30 Biological Evaluation sections of which are hereby incorporated by reference.
  • the in vivo activity of the compounds of the present invention may be assessed by standard techniques, for example by measuring inhibition of cell growth and assessing cytotoxicity.
  • Inhibition of cell growth may be measured by staining cells with Sulforhodamine B (SRB), a fluorescent dye that stains proteins and therefore gives an estimation of amount of protein (i.e. cells) in a well (see Boyd, M.R.(1989) Status of the NCI preclinical antitumour drug discovery screen. Prin. Prac Oncol 10:1-12). Thus, the following details are provided of measuring inhibition of cell growth:-
  • SRB Sulforhodamine B
  • Cells were plated in appropriate medium in a volume of 100ml in 96 well plates; media was Dulbecco's Modified Eagle media for MCF-7, SK-UT-1B and SK-UT-1. The cells were allowed to attach overnight, then inhibitor compounds were added at various concentrations in a maximum concentration of 1% DMSO (v/v). A control plate was assayed to give a value for cells before dosing. Cells were incubated at 37°C, (5% CO 2 ) for three days.
  • Typical IC50 values for compounds of the invention when tested in the SRB assay are in the range ImM to lnM.
  • a pharmaceutical composition which comprises a pyrimidine derivative of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier.
  • the composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.
  • parenteral injection including intravenous, subcutaneous, intramuscular, intravascular or infusion
  • a sterile solution, suspension or emulsion for topical administration as an ointment or cream or for rectal administration as a suppository.
  • the above compositions may be prepared in a conventional manner using conventional excipients.
  • the compound of formula (I) will normally be administered to a warm-blooded animal at a unit dose within the range 5-5000 mg per square meter body area of the animal, i.e. approximately 0.1-100 mg/kg, and this normally provides a therapeutically-effective dose.
  • a unit dose form such as a tablet or capsule will usually contain, for example 1-250 mg of active ingredient.
  • Preferably a daily dose in the range of 1-50 mg/kg is employed.
  • the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.
  • the compounds defined in the present invention are effective cell cycle inhibitors (anti-cell proliferation agents), which property is believed to arise from their CDK inhibitory properties. Accordingly the compounds of the present invention are expected to be useful in the treatment of diseases or medical conditions mediated alone or in part by CDK enzymes, i.e. the compounds may be used to produce a CDK inhibitory effect in a warm-blooded animal in need of such treatment.
  • the compounds of the present invention provide a method for treating the proliferation of malignant cells characterised by inhibition of CDK enzymes, i.e. the compounds may be used to produce an anti-proliferative effect mediated alone or in part by the inhibition of CDKs.
  • Such a compound of the invention is expected to possess a wide range of anti-cancer properties as CDKs have been implicated in many common human cancers such as leukaemia and breast, lung, colon, rectal, stomach, prostate, bladder, pancreas and ovarian cancer. Thus it is expected that a compound of the invention will possess anti-cancer activity against these cancers. It is in addition expected that a compound of the present invention will possess activity against a range of leukaemias, lymphoid malignancies and solid tumours such as carcinomas and sarcomas in t ssues such as the liver, kidney, prostate and pancreas.
  • such compounds of the invention are expected to slow advantageously the growth of primary and recurrent solid tumours of, for example, the colon, breast, prostate, lungs and skin. More particularly such compounds of the invention, or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, are expected to inhibit the growth of those primary and recurrent solid tumours which are associated with CDKs, especially those tumours which are significantly dependent on CDKs for their growth and spread, including for example, certain tumours of the colon, breast, prostate, lung, vulva and skin.
  • a compound of the present invention will possess activity against other cell-proliferation diseases in a wide range of other disease states including leukaemias, fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation.
  • a compound of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore for use as a medicament and the use of a compound of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore in the manufacture of a medicament for use in the production of a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal such as man.
  • an inhibitory effect is produced by preventing entry into or progression through the S phase by inhibition of CDK2, CDK4 and/or CDK6, especially CDK2.
  • cancers solid tumours and leukaemias
  • fibroproliferative and differentiative disorders psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation
  • a method for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound as defined immediately above.
  • an inhibitory effect is produced by preventing entry into or progression through the S phase by inhibition of CDK2, CDK4 and/or CDK6, especially CDK2.
  • a method for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound as defined immediately above or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof.
  • an inhibitory effect is produced by preventing entry into or progression through the S phase by inhibition of CDK2, CDK4 and/or CDK6, especially CDK2.
  • a method of treating cancers in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound as defined immediately above or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof.
  • the size of the dose required for the therapeutic or prophylactic treatment of a particular cell-proliferation disease will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated.
  • a unit dose in the range, for example, 1-100 mg/kg, preferably 1-50 mg/kg is envisaged.
  • the CDK inhibitory activity defined hereinbefore may be applied as a sole therapy or may involve, in addition to a compound of the invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment.
  • the other component(s) of such conjoint treatment in addition to the cell cycle inhibitory treatment defined hereinbefore may be: surgery, radiotherapy or chemotherapy.
  • Such chemotherapy may cover three main categories of therapeutic agent:
  • cytostatic agents such as antioestrogens (for example tamoxifen,toremifene, raloxifene, droloxifene, iodoxyfene), progestogens (for example megestrol acetate), aromatase inhibitors (for example anastrozole, letrazole, vorazole, exemestane), antiprogestogens, antiandrogens (for example flutamide, nilutamide, bicalutamide, cyproterone acetate), LHRH agonists and antagonists (for example goserelin acetate, luprolide), inhibitors of testosterone 5 ⁇ -dihydroreductase (for example finasteride), anti-invasion agents (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase
  • antioestrogens for example tamoxifen,toremifene, raloxi
  • antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology such as antimetabolites (for example antifolates like methotrexate, fluoropyrimidines like 5-fluorouracil, purine and adenosine analogues, cytosine arabinoside); antitumour antibiotics (for example anthracyclines like doxorubicin, daunomycin, epirubicin and idarubicin, mitomycin-C, dactinomycin, mithramycin); platinum derivatives (for example cisplatin, carboplatin); alkylating agents (for example nitrogen mustard, melphalan, chlorambucil, busulphan, cyclophosphamide, ifosfamide, nitrosoureas, thiotepa); antimitotic agents (for example vinca alkaloids like vincrisitine and taxoids like taxol, taxotere); topoisome
  • antimetabolites
  • a pharmaceutical product comprising a compound of the formula (I) as defined hereinbefore and an additional anti-tumour substance as defined hereinbefore for the conjoint treatment of cancer.
  • the compounds of formula (I) and their pharmaceutically acceptable salts are also useful as pharmacological tools in the development and standardisation of in vitro and in vivo test systems for the evaluation of the effects of inhibitors of cell cycle activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
  • the alternative and preferred embodiments of the compounds of the invention described herein also apply. Examples
  • temperatures are given in degrees Celsius (°C); operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18-25°C;
  • chromatography means flash chromatography on silica gel; thin layer chromatography (TLC) was carried out on silica gel plates;
  • NMR data when given, NMR data is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300 MHz using perdeuterio dimethyl sulphoxide (DMSO-d 6 ) as solvent unless otherwise indicated;
  • Example 29 4-Amino-5-cyano-2- ⁇ 4-[N-(2-NN-dimethylaminoethyl)sulphamoyl]anilino ⁇ pyrimidine 2-Dimethylaminoethylamine (2ml) was added to 4-amino-5-cyano-2-(4- fluorosulphonylanilino)pyrimidine (Method 1; 250mg, 0.853mmol) and the mixture was stirred at ambient temperature for 2 hours. The volatiles were removed by evaporation and residue was purified by chromatography eluting with ethyl acetate / hexane /methanol (50:50:0) increasing in polarity to (95 :0:5).
  • the above formulations may be obtained by conventional procedures well known in the pharmaceutical art.
  • the tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compounds of formula (I) wherein: R1 is halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, C1-6alkyl, C2-6alkenyl or C2-6alkynyl; p is 0-4; wherein the values of R1 may be the same or different; R2 is sulphamoyl or a group B-E-; wherein B is optionally substituted as defined within and is selected from C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, C1-6alkyl, phenyl, a heterocyclic group, phenylC1-6alkyl or (heterocyclic group)C1-6alkyl; E is C(O)-, N(Ra)C(O)-, -C(O)N(Ra)-, -S(O)r-, -SO2N(Ra)- or -N(Ra)SO2-; wherein Ra is hydrogen or C1-6alkyl optionally substituted as defined within and r is 1-2; q is 0-2; wherein the values of R2 may be the same or different; and wherein p + q = 1-5; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof are described. Processes for their manufacture and their use as inhibitors of cell cycle kinases, particularly CDK2, CDK4 and/or CDK6 are also described.

Description

4-AMINO-5-CYANO-2-ANILINO-PYRIMIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CELL-CYCLE KINASES
The invention relates to pyrimidine derivatives, or pharmaceutically acceptable salts or in vivo hydrolysable esters thereof, which possess cell-cycle inhibitory activity and are accordingly useful for their anti-cell-proliferation (such as anti-cancer) activity and are therefore useful in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said pyrimidine derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cell-proliferation effect in a warm-blooded animal such as man. A family of intracellular proteins called cyclins play a central role in the cell cycle.
The synthesis and degradation of cyclins is tightly controlled such that their level of expression fluctuates during the cell cycle. Cyclins bind to cyclin-dependent serine/threonine kinases (CDKs) and this association is essential for CDK (such as CDK1, CDK2, CDK4 and/or CDK6) activity within the cell. Although the precise details of how each of these factors combine to regulate CDK activity is poorly understood, the balance between the two dictates whether or not the cell will progress through the cell cycle.
The recent convergence of oncogene and tumour suppressor gene research has identified regulation of entry into the cell cycle as a key control point of mitogenesis in tumours. Moreover, CDKs appear to be downstream of a number of oncogene signalling pathways. Disregulation of CDK activity by upregulation of cyclins and/or deletion of endogenous inhibitors appears to be an important axis between mitogenic signalling pathways and proliferation of tumour cells.
Accordingly it has been recognised that an inhibitor of cell cycle kinases, particularly inhibitors of CDK2, CDK4 and/or CDK6 (which operate at the S-phase, Gl-S and Gl-S phase respectively) should be of value as a selective inhibitor of cell proliferation, such as growth of mammalian cancer cells.
The present invention is based on the discovery that certain pyrimidine compounds surprisingly inhibit the effects of cell cycle kinases showing selectivity for CDK2, CDK4 and CDK6, and thus possess anti-cell-proliferation properties. Such properties are expected to be of value in the treatment of disease states associated with aberrant cell cycles and cell proliferation such as cancers (solid tumours and leukemias), fibroproliferative and differentiative disorders , psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation. Accordingly, the present invention provides a compound of formula (I):
Figure imgf000003_0001
0) wherein:
R1 is halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, C,.6alkyl, C2.6alkenyl or C2-6alkynyl; p is 0-4; wherein the values of R1 may be the same or different;
R2 is sulphamoyl or a group B-E-; wherein
B is selected from C^alkyl, C2-6alkenyl, C2-6alkynyl, C3.8cycloalkyl, C3.gcycloalkylC,.6alkyl, phenyl, a heterocyclic group, phenylC^alkyl or (heterocyclic group)C1.6alkyl; wherein said Chalky!, C2.6alkenyl, C2.6alkynyl, C3.gcycloalkyl, C3.8cycloalkylC1.6alkyl, phenyl, heterocyclic group, phenylCj.galkyl or (heterocyclic group)C!.6alkyl are optionally substituted on carbon by one or more D; and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from G; E is -C(O)-, -N(Ra)C(O)-, -C(O)N(Ra)-, -S(O)r-, -SO2N(Ra)- or -N(Ra)SO2-; wherein Ra is hydrogen or .galkyl optionally substituted by one or more D and r is 1-2;
D is independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-6alkyl, C2.6alkenyl, C2.6alkynyl,
Figure imgf000003_0002
NN-(C1.6alkyl)2amino, C1.6alkanoylamino,
Figure imgf000003_0003
NN-(C1.6alkyl)2carbamoyl, C1.6alkylS(O)a wherein a is 0 to 2, CLgalkoxycarbonyl,
Figure imgf000003_0004
and NN-(C,.6alkyl)2Sulphamoyl; G is selected from CMalkyl, C^alkanoyl, CMalkylsulphonyl, CMalkoxycarbonyl, carbamoyl, N-(CMalkyl)carbamoyl, NN-(CMalkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; and q is 0-2; wherein the values of R2 maybe the same or different; and wherein p + q = 1- 5; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.
In another aspect of the invention, there is provided a compound of formula (I) or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof with the proviso that that compound is not 2-(2,4-dimethylanilino)-4-amino-5-cyanopyrimidine. In this specification the term "alkyl" includes both straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl" are specific for the straight chain version only. For example, "Cι.6alkyl" includes CMalkyl, C^alkyl, propyl, isopropyl and t-butyl. However, references to individual alkyl groups such as 'propyl' are specific for the straight chained version only and references to individual branched chain alkyl groups such as 'isopropyl' are specific for the branched chain version only. A similar convention applies to other radicals, for example "phenylCι_6alkyl" includes phenylC1.4alkyl, benzyl, 1-phenylethyl and 2-phenylethyl. The term "halo" refers to fluoro, chloro, bromo and iodo.
Where optional substituents are chosen from "one or more" groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups.
A "heterocyclic group" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 4-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH2- group can optionally be replaced by a -C(O)-, a ring nitrogen atom may optionally bear a C^aHcyl group and form a quaternary compound or a ring nitrogen and/or sulphur atom may be optionally oxidised to form the N-oxide and or the S-oxides. Examples and suitable values of the term "heterocyclic group" are morpholino, piperidyl, pyridyl, pyranyl, pyrrolyl, isothiazolyl, indolyl, quinolyl, thienyl, 1,3-benzodioxolyl, thiadiazolyl, piperazinyl, thiazolidinyl, pyrrolidinyl, thiomo holino, pyrrolinyl, homopiperazinyl, 3,5- dioxapiperidinyl, tetrahydropyranyl, imidazolyl, pyrimidyl, pyrazinyl, pyridazinyl, isoxazolyl, N-methylpyrrolyl, 4-pyridone, 1-isoquinolone, 2-pyrrolidone, 4-thiazolidone, pyridine-N-oxide and quinoline-N-oxide. Preferably a "heterocyclic group" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, it may, unless otherwise specified, be carbon or nitrogen linked, a -CH2- group can optionally be replaced by a -C(O)-and a ring sulphur atom may be optionally oxidised to form the S-oxides. More preferably a "heterocyclic group" is tetrahydrofuryl, pyridyl, pyrrolidinonyl, morpholino, imidazolyl, piperidinyl or pyrrolidinyl.
An example of "C,.6alkanoyloxy" is acetoxy. Examples of "Cι.6alkoxycarbonyl" include CMalkoxycarbonyl, methoxycarbonyl, ethoxycarbonyl, n- and t-butoxycarbonyl. Examples of "C^alkoxy" include methoxy, ethoxy and propoxy. Examples of "C^alkanoylamino" include formamido, acetamido and propionylamino. Examples of "C1.6alkylS(O)a wherein a is 0 to 2" include Cj.4alkylsulphonyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl. Examples of "C1.6alkylS(O)r wherein r is 1 to 2" include methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl. Examples of "C^alkanoyl" include CMalkanoyl, propionyl and acetyl. Examples of "N-C^alkylamino" include methylamino and ethylamino. Examples of "NN-(C,.6alkyl)2amino" include di-N-methylamino, di-(N-ethyl)amino and N-ethyl-N-methylamino. Examples of "C2.6alkenyl" are vinyl, allyl and 1-propenyl. Examples of "C2-6alkynyl" are ethynyl, 1-propynyl and 2-propynyl. Examples of
Figure imgf000005_0001
are N-(methyl)sulphamoyl and N-(ethyl)sulphamoyl. Examples of "N-(C1.6alkyl)2sulphamoyl" are N,N-(dimethyl)sulphamoyl and
N-(methyl)-N-(ethyl)sulphamoyl. Examples of "N-(Cι.6alkyl)carbamoyl" are N-(C1.4alkyl)carbamoyl, methylaminocarbonyl and ethylaminocarbonyl. Examples of "N,N-(C1.6alkyl)2carbamoyl" are N,N-(C1.4alkyl)2carbamoyl, dimethylaminocarbonyl and methylethylaminocarbonyl. Examples of "C3.8cycloalkyl" are cyclopropyl, cyclobutyl, cyclopropyl and cyclohexyl. Examples of "(heterocyclic group)C,.6alkyl" include pyridylmethyl, 3-morpholinopropyl and 2-pyrimid-2-ylethyl. Examples of "C3_8cycloalkylC1.6alkyl" are cyclopropylethyl, cyclobutylmethyl, 2-cyclopropylpropyl and cyclohexylethyl.
A suitable pharmaceutically acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid. In addition a suitable pharmaceutically acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
The compounds of the formula (I) may be administered in the form of a pro-drug which is broken down in the human or animal body to give a compound of the formula (I). Examples of pro-drugs include in vivo hydrolysable esters of a compound of the formula (I). An in vivo hydrolysable ester of a compound of the formula (I) containing carboxy or hydroxy group is, for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol. Suitable pharmaceutically acceptable esters for carboxy include
Figure imgf000006_0001
esters for example methoxymethyl, Cι_6alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C3.8cycloalkoxycarbonyloxyC1.6alkyl esters for example 1-cyclohexylcarbonyloxyethyl; l,3-dioxolen-2-onylmethyl esters for example 5-methyl-l,3-dioxolen-2-onylmethyl; and C^alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.
An in vivo hydrolysable ester of a compound of the formula (I) containing a hydroxy group includes inorganic esters such as phosphate esters and α-acyloxyalkyl ethers and related compounds which as a result of the in vivo hydrolysis of the ester breakdown to give the parent hydroxy group. Examples of -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy. A selection of in vivo hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and N-(dialkylaminoethyl)-N-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl. Examples of substituents on benzoyl include morpholino and piperazino linked from a ring nitrogen atom via a methylene group to the 3- or 4- position of the benzoyl ring. Some compounds of the formula (I) may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such optical, diastereoisomers and geometric isomers that possess CDK inhibitory activity. The invention relates to any and all tautomeric forms of the compounds of the formula (I) that possess CDK inhibitory activity.
It is also to be understood that certain compounds of the formula (I) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which possess CDK inhibitory activity.
Preferred values of R1, R2, p and q are as follows. Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter. Preferably R1 is halo or C1-2alkyl.
More preferably R1 is fluoro, chloro or methyl.
Particularly R1 is fluoro or chloro.
More particularly R1 is chloro.
Preferably R1 is meta or para to the amino group of the aniline in formula (I). More preferably R1 is meta to the amino group of the aniline in formula (I).
Preferably p is 0-2; wherein the values of R1 may be the same or different.
More preferably p is 0 or 1.
In one aspect of the invention preferably p is 0.
In another aspect of the invention preferably p is 1. In a further aspect of the invention preferably p is 2; wherein the values of R1 may be the same or different.
Preferably R2 is sulphamoyl or a group B-E-; wherein
B is selected from C^alkyl, C2-6alkenyl, C3.8cycloalkyl, C3.8cycloalkylC1.6alkyl, phenylCι.6alkyl or (heterocyclic group)Cι.6alkyl; wherein said C^alkyl, C2.6alkenyl, C3.8cycloalkyl3 C3.8cycloalkylC1.6alkyl, phenylCι.6alkyl or (heterocyclic
Figure imgf000007_0001
are optionally substituted on carbon by one or more D; and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from G;
E is -N(R )SO2-; wherein Ra is hydrogen; D is independently selected from halo, hydroxy, C1-6alkoxy or N- .gaiky amino,
NN-(C1.6alkyl)2amino; and
G is C^alkyl. More preferably R2 is sulphamoyl or a group B-E-; wherein B is optionally substituted by D and is selected from ethyl, propyl, pentyl, allyl, cyclopropyl, cyclobutyl, cyclopropylmethyl, benzyl, phenethyl, tetrahydrofurylmethyl, pyridylethyl, pyrrolidinonylpropyl, morpholinopropyl, imidazolylpropyl, piperidinylethyl, pyrrolidinylethyl (optionally substituted on the ring nitrogen by methyl), E is -NHSO2-;
D is independently selected from fluoro, hydroxy, methoxy, ethoxy, isopropoxy, isopropylamino and dimethylamino.
Particularly R2 is selected from sulphamoyl, N-(cyclopropyhnethyl)sulphamoyl, N-(tetrahydrofur-2-ylmethyl)sulphamoyl, N-(2-methoxyethyl)sulphamoyl, N-(2-pyrid-2-ylethyl)sulphamoyl, N-(2-piperidin- 1 -ylethyl)sulphamoyl, N-[2-(l-methylpyrrolidin-2-yl)ethyl]sulphamoyl, N-(2-isopropylaminoethyl)sulphamoyl, N-(2,2,2-trifluoroethyl)sulphamoyl, N-(3-methoxypropyl)sulphamoyl, N-(3-ethoxypropyl)sulphamoyl, N-(3-isopropoxypropyl)sulphamoyl, N-(3-dimethylaminopropyl)sulphamoyl, N- [3 -(2-oxopyrrolidin-l-yl)propyl] sulphamoyl, N-(3-morpholinopropyl)sulphamoyl, N-(3-imidazol-l-ylpropyl)sulphamoyl, N-(3-isopropylaminopropyl)sulphamoyl, N-(propyl)sulphamoyl, N-(pentyl)sulphamoyl, N-(allyl)sulphamoyl, N-(cyclopropyl)sulphamoyl, N-(cyclobutyl)sulphamoyl, N-(3-methoxybenzyl)sulphamoyl, N-(4-fluorobenzyl)sulphamoyl, N-(phenethyl)sulphamoyl, N-(4-hydroxyphenethyl)sulphamoyl and N-(4-methoxyphenethyl)sulphamoyl.
In another aspect of the invention, preferably R2 is sulphamoyl or a group B-E-; wherein
B is selected from C1-6alkyl, C2.6alkenyl, C3.8cycloalkyl, C3.8cycloalkylCι.6alkyl,
Figure imgf000008_0001
C2.6alkenyl, C3.8cycloalkyl, C3.8cycloalkylCι.6alkyl, phenylC^alkyl or (heterocyclic group)C1-6alkyl are optionally substituted on carbon by one or more D; and wherein if said heterocyclic group contains an -ΝH- moiety that nitrogen may be optionally substituted by a group selected from G;
E is -Ν(Ra)SO2- or -N(Ra)C(O)-; wherein Ra is hydrogen; D is independently selected from halo, hydroxy, C^alkoxy or N-(Cι.6alkyl)amino,
NN-(C1.6alkyl)2amino; and G is CMalkyl. In another aspect of the invention, more preferably R2 is sulphamoyl or a group B-E-; wherein
B is optionally substituted by D and is selected from ethyl, propyl, pentyl, 2,2-dimethylpropyl, allyl, cyclopropyl, cyclobutyl, cyclopropylmethyl, benzyl, phenethyl, tetrahydrofurylmethyl, pyridylethyl, pyrrolidinonylpropyl, morpholinopropyl, imidazolylpropyl, piperidinylethyl, pyrrolidinylethyl (optionally substituted on the ring nitrogen by methyl),
E is -NHSO2- or -N(Ra)C(O)-;
D is independently selected from fluoro, hydroxy, methoxy, ethoxy, isopropoxy, isopropylamino and dimethylamino.
In another aspect of the invention, particularly R2 is selected from sulphamoyl, N-(cyclopropylmethyl)sulphamoyl, N-(tetrahydrofur-2-ylmethyl)sulphamoyl, N-(2-methoxyethyl)sulphamoyl, N-(2-pyrid-2-ylethyl)sulphamoyl, N-(2-piperidin- 1 -ylethyl)sulphamoyl, N-[2-(l -methylpyrrolidin-2-yl)ethyl]sulphamoyl, N-(2-isopropylaminoethyl)sulphamoyl, N-(2,2,2-trifluoroethyl)sulphamoyl, N-(2-dimethylaminoethyl)sulphamoyl, N-(3-methoxypropyl)sulphamoyl, N-(3-ethoxypropyl)sulphamoyl, N-(3-isopropoxypropyl)sulphamoyl, N-(3-dimethylaminopropyl)sulphamoyl, N-[3-(2-oxopyrrolidin-l-yl)propyl]sulphamoyl, N-(3-morpholinopropyl)sulphamoyl, N-(3-imidazol-l-ylpropyl)sulphamoyl, N-(3-isopropylaminopropyl)sulphamoyl, N-(propyl)sulphamoyl, N-(3-hydroxy-2,2- dimethylpropyl)sulphamoyl, N-(pentyl)sulphamoyl, N-(allyl)sulphamoyl, N-(cyclopropyl)sulphamoyl, N-(cyclobutyl)sulphamoyl, N-(3-methoxybenzyl)sulphamoyl, N-(4-fluorobenzyl)sulphamoyl, N-(phenethyl)sulphamoyl, N-(4-hydroxyphenethyl)sulphamoyl, N-(4-methoxyphenethyl)sulphamoyl and N-(3 -imidazol- 1 -ylpropyl)carbamoyl.
Preferably R2 is meta or para to the amino group of the aniline in formula (I).
More preferably R2 is para to the amino group of the aniline in formula (I).
Preferably E is -ΝHSO2-.
In another aspect of the invention, preferably E is -NHSO2- or -N(Ra)C(O)-. Preferably q is 0 or 1.
In one aspect of the invention preferably q is 0.
In another aspect of the invention preferably q is 1. In a further aspect of the invention preferably q is 2; wherein the values of R2 may be the same or different.
Preferably p + q = 1 or 2.
More preferably p + q = 1. Therefore in one aspect of the invention, there is provided a compound of formula (I) as depicted above wherein:
R1 is halo or C1.2alkyl; p is 0-2; wherein the values of R1 may be the same or different;
R2 is sulphamoyl or a group B-E-; wherein B is selected from C^aHcyl, C2-6alkenyl, C3.8cycloalkyl, C3.8cycloalkylC1.6alkyl, phenylC1-6alkyl or (heterocyclic group)C1.6alkyl; wherein said C^aHcyl, C2-6alkenyl, C3.8cycloalkyl, C3.gcycloalkylCι.6alkyl, phenylC1-6alkyl or (heterocyclic group)C1.6alkyl are optionally substituted on carbon by one or more D; and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from G;
E is -N(Ra)SO2-; wherein Ra is hydrogen;
D is independently selected from halo, hydroxy, C1-6alkoxy or N-(Cwalkyl)amino, NN-(C,.6alkyl)2amino;
G is C:.4alkyl; and q is 0 or 1 ; and p + q = 1 or 2; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.
Therefore in a further aspect of the invention, there is provided a compound of formula (I) as depicted above wherein:
R1 is fluoro, chloro or methyl; p is O or l;
R2 is sulphamoyl or a group B-E-; wherein
B is optionally substituted by D and is selected from ethyl, propyl, pentyl, allyl, cyclopropyl, cyclobutyl, cyclopropylmethyl, benzyl, phenethyl, tetrahydrofurylmethyl, pyridylethyl, pyrrolidinonylpropyl, morpholinopropyl, imidazolylpropyl, piperidinylethyl, pyrrolidinylethyl (optionally substituted on the ring nitrogen by methyl),
E is -ΝHSO2-; D is independently selected from fluoro, hydroxy, methoxy, ethoxy, isopropoxy, isopropylamino and dimethylamino; and q is 0 or 1; and p + q = 1 or 2; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof. Therefore in an additional aspect of the invention, there is provided a compound of formula (I) as depicted above wherein: p is O;
R2 is selected from sulphamoyl, N-(cyclopropylmethyl)sulphamoyl, N-(tetrahydrofur-2-ylmethyl)sulphamoyl, N-(2-methoxyethyl)sulphamoyl, N-(2-pyrid-2-ylethyl)sulphamoyl, N-(2-piperidin- 1 -ylethyl)sulphamoyl,
N-[2-(l-methylpyrrolidin-2-yl)ethyl]sulphamoyl, N-(2-isopropylaminoethyl)sulphamoyl, N-(2,2,2-trifluoroethyl)sulphamoyl, N-(3-methoxypropyl)sulphamoyl, N-(3 -ethoxypropyi)sulpharnoyl, N-(3 -isopropoxypropyl)sulphamoyl, N-(3-dimethylaminopropyl)sulphamoyl, N-[3-(2-oxopyrrolidin-l-yl)propyl]sulphamoyl, N-(3-morpholinopropyl)sulphamoyl, N-(3-imidazol-l-ylpropyl)sulphamoyl,
N-(3 -isopropylaminopropyl)sulphamoyl, N-(propyl)sulphamoyl, N-(pentyl)sulphamoyl, N-(allyl)sulphamoyl, N-(cyclopropyl)sulphamoyl, N-(cyclobutyl)sulphamoyl, N-(3-methoxybenzyl)sulphamoyl, N-(4-fluorobenzyl)sulphamoyl, N-(phenethyl)sulphamoyl, N-(4-hydroxyphenethyl)sulphamoyl and N-(4-methoxyphenethyl)sulphamoyl; and q is l; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.
In another aspect of the invention, preferred compounds of the invention are any one of Examples 1-27 or a pharmaceutically acceptable salt or an in vivo hydrolysable esters thereof. In another aspect of the invention, preferred compounds of the invention are any one of Examples 1-31 or a pharmaceutically acceptable salt or an in vivo hydrolysable esters thereof.
In a further aspect of the invention, preferred compounds of formula (I) are: 4-amino-5-cyano-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine; 4-amino-5-cyano-2-{4-[N-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-amino-5-cyano-2-{4-[N-(4-fluorobenzyl)sulphamoyl]anilino}pyrimidine; 4-amino-5-cyano-2-{4-[N-(3-methoxypropyl)sulphamoyl]anilino}pyrimidine; 4-amino-5-cyano-2-{4-[N-(cyclopropyl)sulphamoyl]anilino}pyrimidine; 4-amino-5-cyano-2-[4-(N-allylsulphamoyl)anilino]pyrimidine; 4-amino-5-cyano-2-[4-(N-propylsulphamoyl)anilino]pyrimidine; 4-amino-5-cyano-2-{4-[N-(2-isopropylaminoethyl)sulphamoyl]anilino}pyrimidine; 4-amino-5-cyano-2- {4- [N-(3-isopropylaminopropyl)sulphamoyl]anilino} pyrimidine; and 4-amino-5-cyano-2-{4-[N-(2-piperidinoethyl)sulphamoyl]anilino}pyrimidine; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.
Preferred aspects of the invention are those which relate to the compound of formula (I) or a pharmaceutically acceptable salt thereof. Another aspect of the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof which process (wherein R1, R2, p and q are, unless otherwise specified, as defined in formula (I)) comprises of: a) reaction of a pyrimidine of formula (II) :
Figure imgf000012_0001
(II) wherein L is a displaceable group; with an aniline of formula (III):
Figure imgf000012_0002
(in) b) reacting a pyrimidine of formula (IN) :
Figure imgf000012_0003
(IV) wherein L is a displaceable group; with ammonia; or c) reacting a compound of formula (V):
Figure imgf000013_0001
(V) with a compound of formula (VI):
R3
Figure imgf000013_0002
(VI) wherein X is O or S; R3 is .galkyl; d) reacting a compound of formula (V) with a compound of formula (VII):
R3
Figure imgf000013_0003
(VII) e) where R2 is sulphamoyl or a group B-E- and E is -NHSO2-; reacting a pyrimidine of formula (VIII):
Figure imgf000013_0004
(VIII) wherein X is a displaceable group; with an amine of formula (IX):
B-NH2 (IX) and thereafter if necessary: i) converting a compound of the formula (I) into another compound of the formula (I); ii) removing any protecting groups; iii) forming a pharmaceutically acceptable salt or in vivo hydrolysable ester.
L is a displaceable group, suitable values for L are for example, a halogeno or sulphonyloxy group, for example a chloro, bromo, methanesulphonyloxy or toluene-4-sulphonyloxy group.
X is a displaceable group, suitable values for L are for example, a halogeno group, for example a fluoro, chloro or bromo group. Preferably X is fluoro.
Specific reaction conditions for the above reactions are as follows, a) and b) Pyrimidines of formula (II) and anilines of formula (III) and pyrimidines of formula (IV) and ammonia may be reacted together: i) in the presence of a suitable solvent for example a ketone such as acetone or an alcohol such as ethanol or butanol or an aromatic hydrocarbon such as toluene or N-methyl pyrrolidine, optionally in the presence of a suitable acid for example an inorganic acid such as hydrochloric acid or sulphuric acid, or an organic acid such as acetic acid or formic acid (or a suitable Lewis acid) and at a temperature in the range of 0°C to reflux, preferably reflux; or ii) under standard Buchwald conditions (for example see J. Am. Chem. Soc, 118, 7215; J. Am. Chem. Soc, 119, 8451; J. Org. Chem., 62, 1568 and 6066) for example in the presence of palladium acetate, in a suitable solvent for example an aromatic solvent such as toluene, benzene or xylene, with a suitable base for example an inorganic base such as caesium carbonate or an organic base such as potassium-t-butoxide, in the presence of a suitable ligand such as 2,2'-bis(diphenylphosphino)-l,r-binaphthyl and at a temperature in the range of 25 to 80°C.
Pyrimidines of the formula (II) and (IV) and anilines of formula (III) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art. c) and d) Compounds of formula (V) and compounds of formula (VI) or formula (VII) are reacted together in a suitable solvent such as N-methylpyrrolidinone or butanol at a temperature in the range of 100-200°C, preferably in the range of 150-170°C. The reaction is preferably conducted in the presence of a suitable base such as, for example, sodium methoxide or potassium carbonate.
Compounds of formula (V) and (VI) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art. e) Compounds of formula (VIII) and compounds of formula (IX) may be reacted together in the presence of a base for example an inorganic base such as caesium carbonate in the presence of an inert solvent such as toluene or tetrahydrofuran, or in the presence of an organic base such as excess (IX) and at a temperature in the range of 25 to 80°C.
Compounds of formula (VIII) wherein X is fluoro may be prepared according to the following scheme:
Figure imgf000015_0001
(Villa)
Compounds of formula (Villa) and (IX) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art. It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group. Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.
It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be used in accordance with standard practice (for illustration see T.W. Green, Protective Groups in Organic Synthesis, John Wiley and Sons, 1991). Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein. A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a t-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine. A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art. 5 As stated hereinbefore the compounds defined in the present invention possesses anti-cell-proliferation activity such as anti-cancer activity which is believed to arise from the
CDK inhibitory activity of the compound. These properties may be assessed, for example, using the procedure set out below:-
Assay 10 The following abbreviations have been used :-
HEPES is N-[2-Hydroxyethyl]piperazine-N-[2-ethanesulfonic acid]
DTT is Dithiothretiol
PMSF is Phenylmethylsulfonyl fluoride
The compounds were tested in an in vitro kinase assay in 96 well format using 15 Scintillation Proximity Assay (SPA - obtained from Amersham) for measuring incorporation of [γ-33-P]-Adenosine Triphosphate into a test substrate (GST-Retinoblastoma protein; GST-
Rb). In each well was placed the compound to be tested (diluted in DMSO and water to correct concentrations) and in control wells either roscovitine as an inhibitor control or DMSO as a positive control. 20 Approximately 0.2μl of CDK2/Cyclin E partially-purified enzyme (amount dependent on enzyme activity) diluted in 25 μl incubation buffer was added to each well then 20μl of
GST-Rb/ATP/ATP33 mixture (containing 0.5μg GST-Rb and 0.2μM ATP and 0.14μCi [γ-33-
P]-Adenosine Triphosphate in incubation buffer), and the resulting mixture shaken gently, then incubated at room temperature for 60 minutes. 25 To each well was then added 150μL stop solution containing (0.8mg/well of Protein
A-PNT S A bead (Amersham)), 20ρM/well of Anti-Glutathione Transferase, Rabbit IgG
(obtained from Molecular Probes), 61mM EDTA and 50mM HEPES pH 7.5 containing
0.05% sodium azide.
The plates were sealed with Topseal-S plate sealers, left for two hours then spun at 30 2500rpm, 1124xg., for 5 minutes. The plates were read on a Topcount for 30 seconds per well. The incubation buffer used to dilute the enzyme and substrate mixes contained 50mM HEPES pH7.5, lOmM MnCL., ImM DTT, lOOμM Sodium vanadate, lOOμMNaF, lOmM Sodium Glycerophosphate, BSA (lmg/ml final). Test substrate In this assay only part of the retinoblastoma protein (Science 1987
Marl3;235(4794):1394-1399; Lee W.H., Bookstein R., Hong F., Young L.J., Shew J.Y., Lee EN.) was used, fused to a GST tag. PCR of retinoblastoma gene encoding amino acids 379- 928 (obtained from retinoblastoma plasmid ATCC pLRbRΝL) was performed, and the sequence cloned into pGEX 2T fusion vector (Smith D.B. and Johnson, K.S. Gene 67, 31 (1988); which contained a tac promoter for inducible expression, internal lac Iq gene for use in any E.Coli host, and a coding region for thrombin cleavage - obtained from Pharmacia Biotech) which was used to amplify amino acids 792-928. This sequence was again cloned into pGEX 2T.
The retinoblastoma 792-928 sequence so obtained was expressed in E.Coli (BL21 (DE3) pLysS cells ) using standard inducible expression techniques, and purified as follows. E.coli paste was resuspended in lOml/g of ΝETΝ buffer (50mM Tris pH 7.5, 120mM ΝaCl, lmM EDTA, 0.5%v/v ΝP-40, ImM PMSF, lug/ml leupeptin, lug/ml aprotinin and lug/ml pepstatin) and sonicated for 2 x 45 seconds per 100ml homogenate. After centrifugation, the supernatant was loaded onto a 10ml glutathione Sepharose column (Pharmacia Biotech, Herts, UK), and washed with NETN buffer. After washing with kinase buffer (50mM HEPES pH 7.5, lOmM MgC12, ImM DTT, ImM PMSF, lug/ml leupeptin, lug/ml aprotinin and lug/ml pepstatin) the protein was eluted with 50mM reduced glutathione in kinase buffer. Fractions containing GST-Rb(792-927) were pooled and dialysed overnight against kinase buffer. The final product was analysed by Sodium Dodeca Sulfate (SDS) PAGE (Polyacrylamide gel) using 8-16% Tris-Glycine gels (Novex, San Diego, USA). CDK2 and Cvclin E
The open reading frames of CDK2 and Cyclin E were isolated by reverse transcriptase-PCR using HeLa cell and activated T cell mRNA as a template and cloned into the insect expression vector pNLl 393 (obtained from Invitrogen 1995 catalogue number: N1392-20). CDK2 and cyclin E were then dually expressed [using a standard virus
Baculogold co-infection technique] in the insect SF21 cell system (Spodoptera Frugiperda cells derived from ovarian tissue of the Fall Army Worm - commercially available). Example production of Cyclin E/CDK2
The following Example provides details of the production of Cyclin E/CDK2 in SF21 cells (in TC100 + 10% FBS(TCS) + 0.2% Pluronic) having dual infection MOI 3 for each virus of Cyclin E & CDK2. 5 SF21 cells grown in a roller bottle culture to 2.33 x 106 cells/ml were used to inoculate
10 x 500 ml roller bottles at 0.2 x 10E6 cells/ml. The roller bottles were incubated on a roller rig at 28°C.
After 3 days (72 hrs.) the cells were counted, and the average from 2 bottles found to be 1.86 x 10E6 cells/ml. (99% viable). The cultures were then infected with the dual viruses at 10 an MOI 3 for each virus.
The viruses were mixed together before addition to the cultures, and the cultures returned to the roller rig 28°C.
After 2 days (48 hrs.) post infection the 5 Litres of culture was harvested. The total cell count at harvest was 1.58 x 10E6 cells/ml.(99% viable). The cells were spun out at 15 2500rpm, 30 mins., 4°C in Heraeus Omnifuge 2.0 RS in 250 ml. lots. The supernatant was discarded. Partial co-purification of Cdk2 and Cyclin E
Sf21 cells were resuspended in lysis buffer (50mM Tris pH 8.2, lOmM MgCl2, ImM DTT, lOmM glycerophosphate, O.lmM sodium orthovanadate, O.lmM NaF, ImM PMSF, 20 lug/ml leupeptin and lug/ml aprotinin) and homogenised for 2 minutes in a 10ml Dounce homgeniser. After centrifugation, the supernatant was loaded onto a Poros HQ/M 1.4/100 anion exchange column (PE Biosystems, Hertford, UK). Cdk2 and Cyclin E were coeluted at the beginning of a 0-1 M NaCl gradient (run in lysis buffer minus protease inhibitors) over 20 column volumes. Co-elution was checked by western blot using both anti-Cdk2 and anti- 25 Cyclin E antibodies (Santa Cruz Biotechnology, California, US).
By analogy, assays designed to assess inhibition of CDK4 and CDK6 may be constructed. CDK2 (EMBL Accession No. X62071) may be used together with Cyclin A or Cyclin E (see EMBL Accession No. M73812), and further details for such assays are contained in PCT International Publication No. WO99/21845, the relevant Biochemical & 30 Biological Evaluation sections of which are hereby incorporated by reference.
Although the pharmacological properties of the compounds of the formula (I) vary with structural change, in general activity possessed by compounds of the formula (I) may be demonstrated at IC50 concentrations or doses in the range 250μM to lnM.
When tested in the above in- vitro assay the CDK2 inhibitory activity of Example 21 was measured as IC50 = 0.033μM and that of Example 23 as IC50 = 0.017μM.
The in vivo activity of the compounds of the present invention may be assessed by standard techniques, for example by measuring inhibition of cell growth and assessing cytotoxicity.
Inhibition of cell growth may be measured by staining cells with Sulforhodamine B (SRB), a fluorescent dye that stains proteins and therefore gives an estimation of amount of protein (i.e. cells) in a well (see Boyd, M.R.(1989) Status of the NCI preclinical antitumour drug discovery screen. Prin. Prac Oncol 10:1-12). Thus, the following details are provided of measuring inhibition of cell growth:-
Cells were plated in appropriate medium in a volume of 100ml in 96 well plates; media was Dulbecco's Modified Eagle media for MCF-7, SK-UT-1B and SK-UT-1. The cells were allowed to attach overnight, then inhibitor compounds were added at various concentrations in a maximum concentration of 1% DMSO (v/v). A control plate was assayed to give a value for cells before dosing. Cells were incubated at 37°C, (5% CO2) for three days.
At the end of three days TCA was added to the plates to a final concentration of 16% (v/v). Plates were then incubated at 4°C for 1 hour, the supernatant removed and the plates washed in tap water. After drying, 100ml SRB dye (0.4% SRB in 1% acetic acid) was added for 30 minutes at 37°C. Excess SRB was removed and the plates washed in 1% acetic acid. The SRB bound to protein was solubilised in lOmM Tris pH7.5 and shaken for 30 minutes at room temperature. The ODs were read at 540nm, and the concentration of inhibitor causing 50% inhibition of growth was determined from a semi-log plot of inhibitor concentration versus absorbance. The concentration of compound that reduced the optical density to below that obtained when the cells were plated at the start of the experiment gave the value for toxicity.
Typical IC50 values for compounds of the invention when tested in the SRB assay are in the range ImM to lnM.
According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a pyrimidine derivative of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier. The composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository. In general the above compositions may be prepared in a conventional manner using conventional excipients.
The compound of formula (I) will normally be administered to a warm-blooded animal at a unit dose within the range 5-5000 mg per square meter body area of the animal, i.e. approximately 0.1-100 mg/kg, and this normally provides a therapeutically-effective dose. A unit dose form such as a tablet or capsule will usually contain, for example 1-250 mg of active ingredient. Preferably a daily dose in the range of 1-50 mg/kg is employed. However the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient. According to a further aspect of the present invention there is provided a compound of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore for use in a method of treatment of the human or animal body by therapy.
We have found that the compounds defined in the present invention, or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, are effective cell cycle inhibitors (anti-cell proliferation agents), which property is believed to arise from their CDK inhibitory properties. Accordingly the compounds of the present invention are expected to be useful in the treatment of diseases or medical conditions mediated alone or in part by CDK enzymes, i.e. the compounds may be used to produce a CDK inhibitory effect in a warm-blooded animal in need of such treatment. Thus the compounds of the present invention provide a method for treating the proliferation of malignant cells characterised by inhibition of CDK enzymes, i.e. the compounds may be used to produce an anti-proliferative effect mediated alone or in part by the inhibition of CDKs. Such a compound of the invention is expected to possess a wide range of anti-cancer properties as CDKs have been implicated in many common human cancers such as leukaemia and breast, lung, colon, rectal, stomach, prostate, bladder, pancreas and ovarian cancer. Thus it is expected that a compound of the invention will possess anti-cancer activity against these cancers. It is in addition expected that a compound of the present invention will possess activity against a range of leukaemias, lymphoid malignancies and solid tumours such as carcinomas and sarcomas in t ssues such as the liver, kidney, prostate and pancreas. In particular such compounds of the invention are expected to slow advantageously the growth of primary and recurrent solid tumours of, for example, the colon, breast, prostate, lungs and skin. More particularly such compounds of the invention, or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, are expected to inhibit the growth of those primary and recurrent solid tumours which are associated with CDKs, especially those tumours which are significantly dependent on CDKs for their growth and spread, including for example, certain tumours of the colon, breast, prostate, lung, vulva and skin.
It is further expected that a compound of the present invention will possess activity against other cell-proliferation diseases in a wide range of other disease states including leukaemias, fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation.
Thus according to this aspect of the invention there is provided a compound of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore for use as a medicament; and the use of a compound of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore in the manufacture of a medicament for use in the production of a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal such as man. Particularly, an inhibitory effect is produced by preventing entry into or progression through the S phase by inhibition of CDK2, CDK4 and/or CDK6, especially CDK2. According to a further feature of the invention, there is provided a compound of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined here before in the manufacture of a medicament for use in the treatment of cancers (solid tumours and leukaemias), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation, particularly in the treatment of cancers. According to a further feature of this aspect of the invention there is provided a method for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound as defined immediately above. Particularly, an inhibitory effect is produced by preventing entry into or progression through the S phase by inhibition of CDK2, CDK4 and/or CDK6, especially CDK2.
According to a further feature of this aspect of the invention there is provided a method for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound as defined immediately above or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof. Particularly, an inhibitory effect is produced by preventing entry into or progression through the S phase by inhibition of CDK2, CDK4 and/or CDK6, especially CDK2.
According to an additional feature of this aspect of the invention there is provided a method of treating cancers in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound as defined immediately above or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof.
As stated above the size of the dose required for the therapeutic or prophylactic treatment of a particular cell-proliferation disease will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated. A unit dose in the range, for example, 1-100 mg/kg, preferably 1-50 mg/kg is envisaged.
The CDK inhibitory activity defined hereinbefore may be applied as a sole therapy or may involve, in addition to a compound of the invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. In the field of medical oncology it is normal practice to use a combination of different forms of treatment to treat each patient with cancer. In medical oncology the other component(s) of such conjoint treatment in addition to the cell cycle inhibitory treatment defined hereinbefore may be: surgery, radiotherapy or chemotherapy. Such chemotherapy may cover three main categories of therapeutic agent:
(i) other cell cycle inhibitory agents that work by the same or different mechanisms from those defined hereinbefore; (ii) cytostatic agents such as antioestrogens (for example tamoxifen,toremifene, raloxifene, droloxifene, iodoxyfene), progestogens (for example megestrol acetate), aromatase inhibitors (for example anastrozole, letrazole, vorazole, exemestane), antiprogestogens, antiandrogens (for example flutamide, nilutamide, bicalutamide, cyproterone acetate), LHRH agonists and antagonists (for example goserelin acetate, luprolide), inhibitors of testosterone 5α-dihydroreductase (for example finasteride), anti-invasion agents (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function) and inhibitors of growth factor function, (such growth factors include for example platelet derived growth factor and hepatocyte growth factor such inhibitors include growth factor antibodies, growth factor receptor antibodies, tyrosine kinase inhibitors and serine/threonine kinase inhibitors); and
(iii) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as antimetabolites (for example antifolates like methotrexate, fluoropyrimidines like 5-fluorouracil, purine and adenosine analogues, cytosine arabinoside); antitumour antibiotics (for example anthracyclines like doxorubicin, daunomycin, epirubicin and idarubicin, mitomycin-C, dactinomycin, mithramycin); platinum derivatives (for example cisplatin, carboplatin); alkylating agents (for example nitrogen mustard, melphalan, chlorambucil, busulphan, cyclophosphamide, ifosfamide, nitrosoureas, thiotepa); antimitotic agents (for example vinca alkaloids like vincrisitine and taxoids like taxol, taxotere); topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan). According to this aspect of the invention there is provided a pharmaceutical product comprising a compound of the formula (I) as defined hereinbefore and an additional anti-tumour substance as defined hereinbefore for the conjoint treatment of cancer. In addition to their use in therapeutic medicine, the compounds of formula (I) and their pharmaceutically acceptable salts are also useful as pharmacological tools in the development and standardisation of in vitro and in vivo test systems for the evaluation of the effects of inhibitors of cell cycle activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents. In the above other pharmaceutical composition, process, method, use and medicament manufacture features, the alternative and preferred embodiments of the compounds of the invention described herein also apply. Examples
The invention will now be illustrated by the following non-limiting examples in which, unless stated otherwise:
(i) temperatures are given in degrees Celsius (°C); operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18-25°C;
(ii) organic solutions were dried over anhydrous magnesium sulphate; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 Pascals;
4.5-30mmHg) with a bath temperature of up to 60°C;
(iii) chromatography means flash chromatography on silica gel; thin layer chromatography (TLC) was carried out on silica gel plates;
(iv) in general, the course of reactions was followed by TLC and reaction times are given for illustration only;
(v) final products had satisfactory proton nuclear magnetic resonance (NMR) spectra and/or mass spectral data; (vi) yields are given for illustration only and are not necessarily those which can be obtained by diligent process development; preparations were repeated if more material was required;
(vii) when given, NMR data is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300 MHz using perdeuterio dimethyl sulphoxide (DMSO-d6) as solvent unless otherwise indicated;
(viii) chemical symbols have their usual meanings; SI units and symbols are used;
(ix) solvent ratios are given in volume:volume (v/v) terms; and
(x) mass spectra were run with an electron energy of 70 electron volts in the chemical ionization (CI) mode using a direct exposure probe; where indicated ionization was effected by electron impact (El), fast atom bombardment (FAB) or electrospray (ESP); values for m/z are given; generally, only ions which indicate the parent mass are reported;
(xi) unless stated otherwise compounds containing an asymmetrically substituted carbon and/or sulphur atom have not been resolved;
(xii) where a synthesis is described as being analogous to that described in a previous example the amounts used are the millimolar ratio equivalents to those used in the previous example;
(xvi) the following abbreviations have been used:
NMP l-methyl-2-pyrrolidinone; and DMSO dimethylsulphoxide.
Example 1
4-Amino-5-cyano-2-(4-sulphamoylanilino)pyrimidine A solution of 4-amino-2-chloro-5-cyanopyrimidine (0.5g, 3.24mmol) and 4- sulphamoylaniline (0.58g, 3.4mmol) in NMP (2ml) was heated at 80°C for 20 hours. The mixture was allowed to cool and was diluted with water. The resulting precipitate was collected by filtration, washed with water and dried under vacuum at 60°C to give the title compound (889mg, 95%). NMR: 7.08 (s, 2H), 7.60 (s, 2H), 7.67 (d, 2H), 7.95 (d, 2H), 8.40 (s, 1H), 10.03 (s, 1H); m z 291 (MH)+.
Example 2
4-Amino-5-cyano-2-{4-[N-(3-dimethylaminopropyl)sulphamoyl]anilino}pyrimidine 3-Dimethylaminopropylamine (3ml) was added to 4-amino-5-cyano-2-(4- fluorosulphonylanilino)pyrimidine (Method 1; 250mg, 0.853mmol), the mixture was heated at 90°C for 45 minutes then stirred at ambient temperature for 18 hours. The volatiles were removed by evaporation and residue was purified by chromatography on silica gel eluting with ethyl acetate / hexane /methanol (50:50:0) increasing in polarity to (80:0:20). The product was triturated with ether and a few drops of methanol and the resulting solid collected by filtration to give the title compound (176mg, 55%). ΝMR: 1.45 (t, 2H), 2.04 (s, 6H), 2.10 ( t, 2H), 2.72 (t, 2H), 7.60 (s, 2H), 7.62 (d, 2H), 7.98 (d, 2H), 8.40 (s, 1H); m/z 376 (MH)+.
Examples 3-20
Following the procedure of Example 2 and using 4-amino-5-cyano-2-(4- fluorosulphonylanilino)pyrimidine (Method 1) and the appropriate amine the following compounds were prepared.
Figure imgf000026_0001
Figure imgf000027_0001
Figure imgf000028_0001
Reaction mixture was heated at 95°C for 2 hours Chromatography eluent was ethyl acetate / hexane (50:50) increasing in polarity to (100:0) Exa ple 21
4-Amino-5-cyano-2-{4-[N-(cyclobutyl)sulphamoyl]anilino}pyrimidine
Cyclobutylamine (2ml) was added to 4-amino-5-cyano-2-(4-fluorosulphonylanilino) pyrimidine (Method 1; 250mg, 0.853mmol), the mixture was heated at 40°C for 1 hour and then stirred at ambient temperature for 18 hours. The volatiles were removed by evaporation and residue was purified by chromatography on silica gel eluting with ethyl acetate / hexane (50:50). The product was triturated with ether /hexane and the resulting solid collected by filtration to give the title compound (91mg, 31%). ΝMR: 1.41-1.50 (m, 2H); 1.62-1.78 (m, 2H); 1.82-1.90 (m, 2H); 3.59 (m, IH); 7.60 (s, 2H); 7.62 (d, 2H); 7.98 (d, 2H); 8.40 (s, IH); m/z: 345 (MH)+.
Examples 21-27
Following the procedure of Example 21 and using 4-amino-5-cyano-2-(4- fluorosulphonylanilino)pyrimidine (Method 1) and the appropriate amine the following compounds were prepared.
Figure imgf000029_0001
Figure imgf000030_0001
Example 28
4-Amino-5-cyano-2-{4-[N-(3-imidazol-l-ylpropyl)carbamoyl]anilino}pyrimidine A solution of 4-amino-2-chloro-5-cyanopyrimidine (200mg, 1.3mmol) and 4-[N-(3- imidazol-l-ylpropyl)carbamoyl]aniline (Method 3; 633mg, 2.6mmol) inΝMP (10ml) was heated at 120°C for 48 hours. The mixture was allowed to cool, was diluted with water and extracted with ethyl acetate. The organic extracts were combined, dried and the solvent removed by evaporation, the residue was triturated with ether/hexane and the product collected by filtration to give the title compound (lOmg, 2%). ΝMR: 1.92 (q, 2H) 3.20 (q, 2H), 4.00 (t, 2H), 6.87 (s, IH), 7.19 (s, IH), 7.55 (s, 2H), 7.62 (s, IH), 7.86 (d, 2H), 8.32 (t, IH), 8.38 (s,lH), 9.90 (s, IH); m z 363 (MH)+.
Example 29 4-Amino-5-cyano-2-{4-[N-(2-NN-dimethylaminoethyl)sulphamoyl]anilino}pyrimidine 2-Dimethylaminoethylamine (2ml) was added to 4-amino-5-cyano-2-(4- fluorosulphonylanilino)pyrimidine (Method 1; 250mg, 0.853mmol) and the mixture was stirred at ambient temperature for 2 hours. The volatiles were removed by evaporation and residue was purified by chromatography eluting with ethyl acetate / hexane /methanol (50:50:0) increasing in polarity to (95 :0:5). The product was triturated with ether and collected by filtration to give the title compound (1 lOmg, 36%). ΝMR: 2.05 (s, 6H), 2.20 ( t, 2H), 2.78 (t, 2H), 7.68-7.70 (m, 3H), 7.98 (d, 2H), 8.40 (s, IH); m z 362 (MH)+. Example 30
4-Amino-5-cyano-2-{4-[N-(3-hydroxy-2.2-dimethylpropyl)sulphamoyl]anilino}pyrimidine
A solution of 4-amino-2-chloro-5 -cyanopyrimidine (150mg, 0.97mmol), 4-[N-(3- hydroxy-2,2-dimethylpropyl)sulphamoyl]aniline (Method 4; 274mg, 1.07mmol) inΝMP (5ml) was heated at 120°C for 24 hours. The mixture was allowed to cool, was diluted with water and extracted with ethyl acetate. The organic extracts were combined, dried and the solvent removed by evaporation, the residue was triturated with ether and the product collected by filtration to give the title compound (187mg, 52%). ΝMR: 0.72 (s, 6H), 2.52 (d, 2H), 3.08 (d, 2H), 4.40 (t, IH), 7.19 (t, IH), 7.60 (s, IH), 7.64 (d, 2H), 7.96 (d, 2H), 8.40 (s, IH); m/z 375 (M-HY.
Example 31
4-Amino-5-cyano-2-(3-chloroanilino)pyrimidine
3-Chloroaniline (277mg, 2.2mmol) was treated with 4-amino-2-chloro-5- cyanopyrimidine (0.3g, 2.0mmol) by the procedure described in Example 1 to give the title compound (430mg, 90%). ΝMR: 7.00 (d, IH), 7.28 (dd, IH), 7.55 (s, 2H), 7.70 (d, IH), 7.89 (s, IH), 8.38 (s, IH), 9.81 (s, IH); m/z 246 (MH)+.
Preparation of Starting Materials The starting materials for the Examples above are either commercially available or are readily prepared by standard methods from known materials. For example the following reactions are illustrations but not limitations of the preparation of some of the starting materials used in the above reactions.
Method 1
4-Amino-5-cyano-2-(4-fluorosulphonylanilino)pyrimidine
A solution of 4-amino-2-chloro-5 -cyanopyrimidine (8.0g, 52mmol) and sulphanilyl fluoride (9.07g, 52mmol) in ΝMP (155ml) was heated at 120°C for 24 hours. The mixture was allowed to cool and was diluted with water. The resulting precipitate was collected by filtration, washed with water and dried under vacuum at 60°C for 2 hours. The crude product was recrystallized from ethyl acetate / hexane to give the title compound (5.45g, 37%). ΝMR: 7.70 (s, 2H), 7.93 (d, 2H), 8.15 (d, 2H), 8.45 (s, IH); m z: 292 (MH)+. Method 2
4-[N-(3-imidazol-l-ylpropyl)carbamoyl]nitrobenzene
A solution of l-(3-aminopropyl)imidazole (3.87ml, 33mmol) in ethanol (65ml) was added to 4-nitrobenzoyl chloride (4.0g, 22mmol) and the mixture stirred at ambient temperature for 24 hours. The volatiles were removed by evaporation and the residue was dissolved in ethyl acetate, washed with water and dried. The solvent was removed by evaporation, the residue was triturated with hexane and the product collected by filtration to give the title compound (3.2g, 55%). ΝMR: 1.98 (t, 2H), 3.24 (q, 2H), 4.01 (t, 2H), 6.87 (s, IH), 7.19 (s, IH), 7.64 (s, 2H), 8.15 (d, 2H), 8.30 (d, 2H); 8.80 (t, IH); m/z 275 (MH)+.
Method 3
4- [N-(3 -imidazol- 1 -ylpropyl)carbamoyl] aniline
10% Palladium on carbon (500mg) was added to a solution of 4-[N-(imidazol-l- ylpropyl)carbamoyl]nitrobenzene (Method 2; 3.0g, llmmol) dissolved in ethanol (200ml) and ethyl acetate (50ml). The mixture was stirred under hydrogen for 2 hours, the catalyst removed by filtration through diatomaceous earth and the filter pad washed through with methanol. The solvent was removed from the filtrate by evaporation to give the title compound (1.5g, 57%). ΝMR: 1.91 (t, 2H), 3.19 (q, 2H), 3.98 (t, 2H), 5.58 (s, 2H), 6.52 (d, 2H), 6.86 (s, IH), 7.19 (s, IH), 7.58 (d, 2H), 7.62 (s, IH); 8.00 (t, IH); m/z 245 (MH)+.
Method 4 4-[N-(3-hydroxy-2.2-dimethylpropyl)sulphamoyl]aniline
A mixture of sulphanilyl fluoride (lg, 5.7mmol), 3-amino-2,2-dimethylpropan-l-ol (884mg, 8.6mmol) and triethylamine (0.876ml, 6.3mmol) in butan-1-ol (20ml) was heated at reflux for 24 hours. The volatiles were removed by evaporation and residue was purified by chromatography on silica gel to give the title compound. ΝMR: 0.72 (s, 6H), 2.52 (d, 2H), 3.08 (d, 2H), 4.40 (t, IH), 7.19 (t, IH), 7.60 (s, IH), 7.64 (d, 2H), 7.96 (d, 2H), 8.40 (s, IH); m/z 259 (MH)+.
Example 32
The following illustrate representative pharmaceutical dosage forms containing the compound of formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof (hereafter compound X), for therapeutic or prophylactic use in humans:-
Figure imgf000033_0001
Figure imgf000034_0001
Note The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.

Claims

Claims:
1. A compound of formula (I) :
Figure imgf000035_0001
(I) wherein:
R1 is halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, C^aHcyl, C2.6alkenyl or C2.6alkynyl; p is 0-4; wherein the values of R1 may be the same or different; R2 is sulphamoyl or a group B-E-; wherein
B is selected from C1-6alkyl, C2.6alkenyl, C2-6alkynyl, C3.8cycloalkyl, C3.8cycloalkylCl.6alkyl, phenyl, a heterocyclic group, phenylCLgalkyl or (heterocyclic group)C!.6alkyl; wherein said C^a-kyl, C2.6alkenyl, C2.6alkynyl, C3.8cycloalkyl, C3.8cycloalkylC1.6alkyl, phenyl, heterocyclic group, phenylCLgalkyl or (heterocyclic group)C1.6alkyl are optionally substituted on carbon by one or more D; and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from G;
E is -C(O)-, -N(Ra)C(O)-, -C(O)N(Ra)-, -S(O)r-, -SO2N(Ra)- or -N(Ra)SO2-; wherein Ra is hydrogen or C,.6alkyl optionally substituted by one or more D and r is 1-2; D is independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl,
Figure imgf000035_0002
C2-6alkenyl, C2.6alkynyl,
Figure imgf000035_0003
N-(Cu6alkyl)amino, N,N-(Cμ6alkyl)2amino,
Figure imgf000035_0004
N,N-(C 6alkyι)2carbarnoyl, C1.6alkylS(O)a wherein a is 0 to 2, CLgalkoxycarbonyl, N-(Cι.6alkyl)sulphamoyl and NN^C^alkyl^sulphamoyl;
G is selected from C,.4alkyl, C^alkanoyl, C,.4alkylsulphonyl, C^alkoxycarbonyl, carbamoyl, N-(CMalkyl)carbamoyl, NN-(C1.4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; and q is 0-2; wherein the values of R2 maybe the same or different; and wherein p + q = 1- 5; with the proviso that that compound is not 2-(2,4-dimethylanilino)-4-amino-5- cyanopyrimidine; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.
2. A compound of formula (I) as claimed in claim 1 wherein R1 is chloro; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.
3. A compound of formula (I) as claimed in either of claims 1 or 2 wherein p is 0 or 1 ; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.
4. A compound of formula (I) as claimed in any one of claims 1 - 3 wherein R2 is sulphamoyl or a group B-E-; wherein B is selected from C^alkyl, C2.6alkenyl, C3.8cycloalkyl, C3.8cycloalkylC1.6alkyl, phenylC^alkyl or (heterocyclic group)C1-6alkyl; wherein said Cj.6alkyl, C2-6alkenyl, C3.8cycloalkyl, C3.8cycloalkylC1.6alkyl, phenylC,.6alkyl or (heterocyclic
Figure imgf000036_0001
are optionally substituted on carbon by one or more D; and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from G;
E is -N(Ra)SO2- or -N(Ra)C(O)-; wherein Ra is hydrogen;
D is independently selected from halo, hydroxy, .galkoxy or N-(C,.6alkyl)amino, N,N-(C1.6alkyl)2amino; and G is CMalkyl; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.
5. A compound of formula (I) as claimed in any one of claims 1 - 4 wherein R2 is selected from sulphamoyl, N-(cyclopropylmethyl)sulphamoyL N-(tefrahydrofur-2-ylmethyl)sulphamoyl, N-(2-methoxyethyl)sulphamoyl, N-(2-pyrid-2-ylethyl)sulphamoyl, N-(2-piperidin-l-ylethyl)sulphamoyl,
N-[2-(l-methylpyrrolidin-2-yl)ethyl]sulphamoyl, N-(2-isopropylaminoethyl)sulphamoyl, N-(2,2,2-trifluoroethyl)sulphamoyl, N-(2-dimethylaminoethyl)sulphamoyl, N-(3-methoxypropyl)sulphamoyl, N-(3-ethoxypropyl)sulphamoyl, N-(3 -isopropoxypropyl)sulρhamoyl, N-(3 -dimethylaminopropyl)sulphamoyl, N-[3 -(2-oxopyrrolidin- 1 -yl)propyl] sulphamoyl, N-(3 -morpholinopropyl)sulphamoyl, N-(3-imidazol-l-ylpropyl)sulphamoyl, N-(3-isopropylaminopropyl)sulphamoyl, N-(propyl)sulphamoyl, N-(3-hydroxy-2,2-dimethylpropyl)sulphamoyl, N-(pentyl)sulphamoyL N-(allyl)sulphamoyl, N-(cyclopropyl)sulphamoyl, N-(cyclobutyl)sulphamoyl, N-(3-methoxybenzyl)sulphamoylJ N-(4-fluorobenzyl)sulphamoyl, N-(phenethyl)sulphamoyl, N-(4-hydroxyphenethyl)sulphamoyl, N-(4-methoxyphenethyl)sulphamoyl and N-(3-imidazol-l-ylpropyl)carbamoyl; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.
6. A compound of formula (I) as claimed in any one of claims 1 - 5 wherein q is 0 or 1; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.
7. A compound of formula (I) as claimed in any one of claims 1 - 6 wherein p + q is 1 ; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.
8. A compound of formula (I) as claimed in any one of claims 1 - 7 selected from:
4-amino-5-cyano-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine; 4-amino-5-cyano-2-{4-[N-(tefrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine;
4-amino-5-cyano-2-{4-[N-(4-fluorobenzyl)sulphamoyl]anilino}pyrimidine;
4-amino-5 -cy ano-2- {4- [N-(3 -methoxypropyl)sulphamoyl] anilino } pyrimidine;
4-amino-5-cyano-2-{4-[N-(cyclopropyl)sulphamoyl]anilino}pyrimidine;
4-amino-5-cyano-2-[4-(N-allylsulphamoyl)anilino]pyrimidine; 4-amino-5-cyano-2-[4-(N-propylsulphamoyl)anilino]pyrimidine;
4-amino-5-cyano-2-{4-[N-(2-isopropylaminoethyl)sulphamoyl]anilino}pyrimidine;
4-amino-5-cyano-2-{4-[N-(3-isopropylaminopropyl)sulphamoyl]anilino}pyrimidine; and
4-amino-5-cyano-2-{4-[N-(2-piperidinoethyl)sulphamoyl]anilino}pyrimidine; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof.
9. A process for preparing a compound of formula (I) or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof which process (wherein R1, R2, p and q are, unless otherwise specified, as defined in claim 1) comprises of: a) reaction of a pyrimidine of formula (II):
Figure imgf000038_0001
(II) wherein L is a displaceable group; with an aniline of formula (III):
Figure imgf000038_0002
b) reacting a pyrimidine of formula (IV) :
Figure imgf000038_0003
(IV) wherein L is a displaceable group; with ammonia; or c) reacting a compound of formula (V):
Figure imgf000038_0004
(V) with a compound of formula (VI):
R3
Figure imgf000039_0001
(VI) wherein X is O or S; R3 is C1-6alkyl; d) reacting a compound of formula (V) with a compound of formula (VII):
Figure imgf000039_0002
(VII) e) where R2 is sulphamoyl or a group B-E- and E is -NHSO2-; reacting a pyrimidine of formula (VIII):
Figure imgf000039_0003
(VIII) wherein X is a displaceable group; with an amine of formula (IX):
B-NH2 (IX) and thereafter if necessary: i) converting a compound of the formula (I) into another compound of the formula (I); ii) removing any protecting groups; iii) forming a pharmaceutically acceptable salt or in vivo hydrolysable ester.
10. A pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as claimed in any one of claims 1-8, in association with a pharmaceutically-acceptable diluent or carrier.
11. A compound of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as claimed in any one of claims 1-8, for use in a method of treatment of the human or animal body by therapy.
12. A compound of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as claimed in any one of claims 1-8, for use as a medicament.
13. The use of a compound of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as claimed in any one of claims 1-8, in the manufacture of a medicament for use in the treatment of cancers.
14. A method of treating cancers in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound as claimed in any one of claims 1-8, or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof.
PCT/GB2001/001264 2000-03-28 2001-03-23 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases WO2001072717A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
AU3941401A AU3941401A (en) 2000-03-28 2001-03-23 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases
JP2001570630A JP2003528861A (en) 2000-03-28 2001-03-23 4-Amino-5-cyano-2-anilino-pyrimidine derivatives and their use as cell cycle kinase inhibitors
US10/239,790 US6906065B2 (en) 2000-03-28 2001-03-23 4-Amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases
NZ521032A NZ521032A (en) 2000-03-28 2001-03-23 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as pharmaceutical composiitons for cancer
EP01914026A EP1268445B1 (en) 2000-03-28 2001-03-23 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases
AT01914026T ATE303366T1 (en) 2000-03-28 2001-03-23 4-AMINO-5-CYANO-2-ANILINO-PYRIMIDINE DERIVATIVES FOR USE AS INHIBITORS OF CELL CYCLE KINASES
MXPA02009255A MXPA02009255A (en) 2000-03-28 2001-03-23 4 amino 5 cyano 2 anilino pyrimidine derivatives and their use as inhibitors of cell cycle kinases.
DE60113080T DE60113080T2 (en) 2000-03-28 2001-03-23 4-AMINO-5-CYANO-2-ANILINO-PYRIMIDINE DERIVATIVES FOR USE AS INHIBITORS OF CELL CYCLE KINASES
IL15139201A IL151392A0 (en) 2000-03-28 2001-03-23 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases
AU2001239414A AU2001239414B2 (en) 2000-03-28 2001-03-23 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases
BR0109577-3A BR0109577A (en) 2000-03-28 2001-03-23 Compound, process for preparing same, pharmaceutical composition, use of a compound, and method for treating cancers in a warm-blooded animal
CA002399864A CA2399864A1 (en) 2000-03-28 2001-03-23 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases
IL151392A IL151392A (en) 2000-03-28 2002-08-21 4 - amino - 5 - cyano - 2 - anilino - pyrimidine derivatives and their use as inhibitors of cell-cycle kinases
NO20024644A NO324228B1 (en) 2000-03-28 2002-09-27 4-Amino-5-cyano-2-anilino-pyrimidine derivatives and their use and methods of preparation, as well as pharmaceutical composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0007371.8 2000-03-28
GBGB0007371.8A GB0007371D0 (en) 2000-03-28 2000-03-28 Chemical compounds

Publications (1)

Publication Number Publication Date
WO2001072717A1 true WO2001072717A1 (en) 2001-10-04

Family

ID=9888482

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/001264 WO2001072717A1 (en) 2000-03-28 2001-03-23 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases

Country Status (21)

Country Link
US (1) US6906065B2 (en)
EP (1) EP1268445B1 (en)
JP (1) JP2003528861A (en)
KR (1) KR100802367B1 (en)
CN (1) CN1231471C (en)
AT (1) ATE303366T1 (en)
AU (2) AU3941401A (en)
BR (1) BR0109577A (en)
CA (1) CA2399864A1 (en)
DE (1) DE60113080T2 (en)
DK (1) DK1268445T3 (en)
ES (1) ES2247078T3 (en)
GB (1) GB0007371D0 (en)
IL (2) IL151392A0 (en)
MX (1) MXPA02009255A (en)
MY (1) MY124527A (en)
NO (1) NO324228B1 (en)
NZ (1) NZ521032A (en)
PT (1) PT1268445E (en)
WO (1) WO2001072717A1 (en)
ZA (1) ZA200206957B (en)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593326B1 (en) 1998-12-24 2003-07-15 Astrazeneca Ab 2,4-diamino pyrimidine compounds having anti-cell proliferative activity
WO2003062246A1 (en) * 2002-01-22 2003-07-31 Warner-Lambert Company Llc 2-thia-1,6,8-triaza-naphtalene-2,2-dioxides as cdk inhibitors
US6649608B2 (en) 2000-03-01 2003-11-18 Astrazeneca Ab 2,4-di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents
US6710052B2 (en) 2000-03-01 2004-03-23 Astrazeneca Pyrimidine compounds
WO2004048343A1 (en) * 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
US6838464B2 (en) 2000-03-01 2005-01-04 Astrazeneca Ab 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents
US6844341B2 (en) 2001-02-17 2005-01-18 Astrazeneca Ab Pyrimidine derivatives for inhibition of cell proliferation
US6855719B1 (en) 1999-08-21 2005-02-15 Astrazeneca Ab Imidazo[1,2-A]pyridine and pyrazolo[2,3-A]pyridine derivatives
US6908920B2 (en) 2000-07-11 2005-06-21 Astrazeneca Ab Pyrimidine derivatives
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US6939872B2 (en) 2001-05-30 2005-09-06 Astrazeneca Ab 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors
US6969714B2 (en) 2000-09-05 2005-11-29 Astrazeneca Ab Imidazolo-5-YL-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US7153964B2 (en) 2000-03-01 2006-12-26 Astrazeneca Ab Pyrimidine compounds
US7253174B2 (en) * 2001-06-26 2007-08-07 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
WO2007132010A1 (en) * 2006-05-15 2007-11-22 Boehringer Ingelheim International Gmbh 2, 4 -diamino pyrimidines as cell cycle kinase inhibitors
US7427626B2 (en) 2003-05-16 2008-09-23 Astrazeneca Ab 2-Anilino-4-(imidazol-5-yl)-pyrimidine derivatives and their use as cdk (cdk2) inhibitors
US7442697B2 (en) 2002-03-09 2008-10-28 Astrazeneca Ab 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
US7446105B2 (en) 2002-03-09 2008-11-04 Astrazeneca Ab Pyrimidine compounds
US7485638B2 (en) 2002-03-09 2009-02-03 Astrazeneca Ab Pyrimidine compounds
US7579344B2 (en) 2003-05-16 2009-08-25 Astrazeneca Ab Pyrimidine derivatives possessing cell-cycle inhibitors activity
US7655652B2 (en) 2004-02-03 2010-02-02 Astrazeneca Ab Imidazolo-5-yl-2-anilinopyrimidines as agents for the inhibition of cell proliferation
US7709480B2 (en) 2001-10-17 2010-05-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives
US7713987B2 (en) 2005-12-06 2010-05-11 Rigel Pharmaceuticals, Inc. Pyrimidine-2,4-diamines and their uses
US7745428B2 (en) 2005-09-30 2010-06-29 Astrazeneca Ab Imidazo[1,2-A]pyridine having anti-cell-proliferation activity
US8389533B2 (en) 2008-04-07 2013-03-05 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
US8623885B2 (en) 2011-03-23 2014-01-07 Amgen Inc. Fused tricyclic dual inhibitors of CDK 4/6 and FLT3
US8841312B2 (en) 2007-12-19 2014-09-23 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
CN111686113A (en) * 2019-03-15 2020-09-22 北京大学 Sonic Hedgehog inhibitor and application thereof
US11666888B2 (en) 2018-02-05 2023-06-06 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand
US12097261B2 (en) 2021-05-07 2024-09-24 Kymera Therapeutics, Inc. CDK2 degraders and uses thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513967A (en) * 2003-12-11 2007-05-31 セラヴァンス， インコーポレーテッド Compositions for use in the treatment of cell proliferative diseases driven by mutant receptor tyrosine kinases
WO2006064251A1 (en) * 2004-12-17 2006-06-22 Astrazeneca Ab 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors
AU2006274733B2 (en) * 2005-07-30 2010-09-16 Astrazeneca Ab Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
CN112110863A (en) * 2020-08-27 2020-12-22 中山大学 Sulfonyl fluoride compound, preparation method thereof and method for preparing sulfonamide compound through sulfonyl fluoride compound

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033798A2 (en) * 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
WO2000039101A1 (en) * 1998-12-24 2000-07-06 Astrazeneca Ab Pyrimidine compounds

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659363A (en) 1983-07-25 1987-04-21 Ciba-Geigy Corporation N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof
US4946956A (en) 1988-09-21 1990-08-07 Uniroyal Chemical Company, Inc. Arylenediamine substituted pyrimidines
HU206337B (en) 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
US4983608A (en) 1989-09-05 1991-01-08 Hoechst-Roussell Pharmaceuticals, Inc. N-substituted-4-pyrimidinamines and pyrimidinediamines
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
WO1992020642A1 (en) 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (en) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
DE69329067T2 (en) 1992-10-05 2001-05-10 Ube Industries, Ltd. PYRIDMIDINE DERIVATIVES
NZ273617A (en) 1993-10-01 1996-11-26 Ciba Geigy Ag N-phenyl-2-pyrimidineamine derivatives pharmaceutical compositions
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
US5612340A (en) 1993-10-01 1997-03-18 Ciba-Geigy Corporation Pyrimidineamine derivatives and processes for the preparation thereof
DE69434721T2 (en) 1993-10-01 2006-11-09 Novartis Ag PHARMACOLOGICALLY EFFECTIVE PYRIMIDINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
GB9325217D0 (en) 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
CA2197298C (en) 1994-08-13 1999-10-19 Jong Wook Lee Novel pyrimidine derivatives and processes for the preparation thereof
DK0813525T3 (en) 1995-03-10 2004-02-16 Berlex Lab Benzamidine derivatives, their preparation and use as anticoagulants
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5739143A (en) 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp Imidazole derivatives, process for their preparation and pharmaceutical compositions comprising them
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6096739A (en) 1996-03-25 2000-08-01 Smithkline Beecham Corporation Treatment for CNS injuries
AU2381397A (en) 1996-04-19 1997-11-12 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
JP3418624B2 (en) 1996-06-10 2003-06-23 メルク エンド カンパニー インコーポレーテッド Substituted imidazoles having cytokine inhibitory activity
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
AU5147598A (en) 1996-10-17 1998-05-11 Smithkline Beecham Corporation Methods for reversibly inhibiting myelopoiesis in mammalian tissue
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
DE19710435A1 (en) 1997-03-13 1998-09-17 Hoechst Ag Use of pyrimidine derivatives for the prevention of cancer alone or in combination with other therapeutic measures
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
JP2002501532A (en) 1997-05-30 2002-01-15 メルク エンド カンパニー インコーポレーテッド Novel angiogenesis inhibitors
CZ9904452A3 (en) 1997-06-12 2002-02-13 Rhone-Poulenc Rorer Limited Imidazolyl cyclic acetals, process of their preparation, their use and pharmaceutical preparation in which the acetals are comprised
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
HUP0003194A3 (en) 1997-08-15 2003-03-28 Cephalon Inc West Chester Use of tyrosine kinase inhibitor in synergic pharmaceutical composition treating prostate cancer
EP1019391A1 (en) 1997-10-02 2000-07-19 Merck & Co. Inc. Inhibitors of prenyl-protein transferase
CA2316296A1 (en) 1997-10-10 1999-04-22 Imperial College Of Science, Technology And Medicine Use of csaidtm compounds for the management of uterine contractions
AU1507199A (en) 1997-12-15 1999-07-05 Yamanouchi Pharmaceutical Co., Ltd. Novel pyrimidine-5-carboxamide derivatives
AR017219A1 (en) 1997-12-19 2001-08-22 Smithkline Beecham Corp IMIDAZOL DERIVATIVES 1,4,5 SUBSTITUTES, COMPOSITIONS THAT INCLUDE THEM, PROCEDURE FOR THE PREPARATION OF SUCH DERIVATIVES, USE OF DERIVATIVES TO MANUFACTURE OF A MEDICINAL PRODUCT
EA200000840A1 (en) 1998-02-17 2001-02-26 Туларик, Инк. ANTI-VIRUS DERIVATIVES OF PYRIMIDINE
KR100699514B1 (en) 1998-03-27 2007-03-26 얀센 파마슈티카 엔.브이. HIV inhibiting pyrimidine derivatives
GB9806739D0 (en) 1998-03-28 1998-05-27 Univ Newcastle Ventures Ltd Cyclin dependent kinase inhibitors
DE69932828T2 (en) 1998-08-29 2007-10-18 Astrazeneca Ab PYRIMIDINE COMPOUNDS
AU5438299A (en) 1998-08-29 2000-03-21 Astrazeneca Ab Pyrimidine compounds
PL347138A1 (en) 1998-09-18 2002-03-25 Basf Ag 4-aminopyrrolopyrimidines as kinase inhibitors
JP2002526500A (en) 1998-09-18 2002-08-20 ビーエーエスエフ アクチェンゲゼルシャフト Pyrrolopyrimidines as protein kinase inhibitors
US6531477B1 (en) 1998-10-13 2003-03-11 Dupont Pharmaceuticals Company 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
WO2000025780A1 (en) 1998-10-29 2000-05-11 Bristol-Myers Squibb Company Compounds derived from an amine nucleus that are inhibitors of impdh enzyme
WO2000026209A1 (en) 1998-11-03 2000-05-11 Novartis Ag Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles
GEP20033092B (en) 1999-02-01 2003-10-27 Cv Therapeutics Inc Us Purine Inhibitors of Cyclin Dependent Kinase 2 and Ik-Aa
GB9903762D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
US6627633B2 (en) 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
ES2254238T3 (en) 1999-10-27 2006-06-16 Novartis Ag TIAZOL AND IMIDAZO COMPOUNDS (4,5-B) PIRIDINE AND ITS PHARMACEUTICAL USE.
WO2001037835A1 (en) 1999-11-22 2001-05-31 Smithkline Beecham Plc. Novel compounds
AU2735201A (en) 1999-12-28 2001-07-09 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
HUP0301117A3 (en) 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033798A2 (en) * 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
WO2000039101A1 (en) * 1998-12-24 2000-07-06 Astrazeneca Ab Pyrimidine compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DEADY, L. ET AL.: "Reactions of some quinazoline compounds with ethoxymethylenemalonic acid derivatives", J. HETEROCYCL. CHEM., vol. 26, no. 1, 1989, pages 161 - 8, XP001000831 *
SCHMIDT, HANS WERNER ET AL.: "A convenient synthesis of 2-substituted 4-amino-5-pyrimidinecarbonitriles", J. HETEROCYCL. CHEM., vol. 24, no. 5, 1987, pages 1305 - 7, XP001000522 *
ZIMMERMANN J ET AL: "PHENYLAMINO-PYRIMIDINE (PAP) DERIVATIVES: A NEW CLASS OF POTENT ANDSELECTIVE INHIBITORS OF PROTEIN KINASE C (PKC)", ARCHIV DER PHARMAZIE,DE,VCH VERLAGSGESELLSCHAFT MBH, WEINHEIM, vol. 329, no. 7, July 1996 (1996-07-01), pages 371 - 376, XP000885618, ISSN: 0365-6233 *

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593326B1 (en) 1998-12-24 2003-07-15 Astrazeneca Ab 2,4-diamino pyrimidine compounds having anti-cell proliferative activity
US6855719B1 (en) 1999-08-21 2005-02-15 Astrazeneca Ab Imidazo[1,2-A]pyridine and pyrazolo[2,3-A]pyridine derivatives
US6649608B2 (en) 2000-03-01 2003-11-18 Astrazeneca Ab 2,4-di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents
US6710052B2 (en) 2000-03-01 2004-03-23 Astrazeneca Pyrimidine compounds
US7153964B2 (en) 2000-03-01 2006-12-26 Astrazeneca Ab Pyrimidine compounds
US6838464B2 (en) 2000-03-01 2005-01-04 Astrazeneca Ab 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents
US7067522B2 (en) 2000-03-01 2006-06-27 Astrazeneca Ab 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents
US6908920B2 (en) 2000-07-11 2005-06-21 Astrazeneca Ab Pyrimidine derivatives
US6969714B2 (en) 2000-09-05 2005-11-29 Astrazeneca Ab Imidazolo-5-YL-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
US6844341B2 (en) 2001-02-17 2005-01-18 Astrazeneca Ab Pyrimidine derivatives for inhibition of cell proliferation
US6939872B2 (en) 2001-05-30 2005-09-06 Astrazeneca Ab 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors
US7253174B2 (en) * 2001-06-26 2007-08-07 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
US8044040B2 (en) 2001-06-26 2011-10-25 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-alpha expression
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US8420630B2 (en) 2001-10-17 2013-04-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives
US7709480B2 (en) 2001-10-17 2010-05-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives
WO2003062246A1 (en) * 2002-01-22 2003-07-31 Warner-Lambert Company Llc 2-thia-1,6,8-triaza-naphtalene-2,2-dioxides as cdk inhibitors
US7442697B2 (en) 2002-03-09 2008-10-28 Astrazeneca Ab 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
US7446105B2 (en) 2002-03-09 2008-11-04 Astrazeneca Ab Pyrimidine compounds
US7485638B2 (en) 2002-03-09 2009-02-03 Astrazeneca Ab Pyrimidine compounds
US7504410B2 (en) 2002-11-28 2009-03-17 Schering Aktiengesellschaft Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
WO2004048343A1 (en) * 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
US7579344B2 (en) 2003-05-16 2009-08-25 Astrazeneca Ab Pyrimidine derivatives possessing cell-cycle inhibitors activity
US7427626B2 (en) 2003-05-16 2008-09-23 Astrazeneca Ab 2-Anilino-4-(imidazol-5-yl)-pyrimidine derivatives and their use as cdk (cdk2) inhibitors
US7655652B2 (en) 2004-02-03 2010-02-02 Astrazeneca Ab Imidazolo-5-yl-2-anilinopyrimidines as agents for the inhibition of cell proliferation
US7745428B2 (en) 2005-09-30 2010-06-29 Astrazeneca Ab Imidazo[1,2-A]pyridine having anti-cell-proliferation activity
US7713987B2 (en) 2005-12-06 2010-05-11 Rigel Pharmaceuticals, Inc. Pyrimidine-2,4-diamines and their uses
US8623887B2 (en) 2006-05-15 2014-01-07 Boehringer Ingelheim International Gmbh Compounds
WO2007132010A1 (en) * 2006-05-15 2007-11-22 Boehringer Ingelheim International Gmbh 2, 4 -diamino pyrimidines as cell cycle kinase inhibitors
EP2357181A1 (en) * 2006-05-15 2011-08-17 Boehringer Ingelheim International GmbH 2,4-Diaminopyrimidines as inhibitors of cell cycle kinases
US8841312B2 (en) 2007-12-19 2014-09-23 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
US8980903B2 (en) 2007-12-19 2015-03-17 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
US8389533B2 (en) 2008-04-07 2013-03-05 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
US8623885B2 (en) 2011-03-23 2014-01-07 Amgen Inc. Fused tricyclic dual inhibitors of CDK 4/6 and FLT3
US9359355B2 (en) 2011-03-23 2016-06-07 Amgen Inc. Fused tricyclic dual inhibitors of CDK 4/6 and FLT3
US11666888B2 (en) 2018-02-05 2023-06-06 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand
CN111686113A (en) * 2019-03-15 2020-09-22 北京大学 Sonic Hedgehog inhibitor and application thereof
CN111686113B (en) * 2019-03-15 2022-12-30 北京大学 Sonic Hedgehog inhibitor and application thereof
US12097261B2 (en) 2021-05-07 2024-09-24 Kymera Therapeutics, Inc. CDK2 degraders and uses thereof

Also Published As

Publication number Publication date
AU2001239414B2 (en) 2004-09-02
MY124527A (en) 2006-06-30
DK1268445T3 (en) 2005-11-07
NO324228B1 (en) 2007-09-10
US20030087923A1 (en) 2003-05-08
NO20024644L (en) 2002-11-27
ZA200206957B (en) 2003-12-01
US6906065B2 (en) 2005-06-14
CA2399864A1 (en) 2001-10-04
CN1231471C (en) 2005-12-14
AU3941401A (en) 2001-10-08
PT1268445E (en) 2005-11-30
NO20024644D0 (en) 2002-09-27
KR100802367B1 (en) 2008-02-13
BR0109577A (en) 2003-01-28
JP2003528861A (en) 2003-09-30
ATE303366T1 (en) 2005-09-15
DE60113080D1 (en) 2005-10-06
CN1419548A (en) 2003-05-21
NZ521032A (en) 2004-05-28
IL151392A (en) 2007-06-17
EP1268445A1 (en) 2003-01-02
DE60113080T2 (en) 2006-05-18
KR20020083532A (en) 2002-11-02
EP1268445B1 (en) 2005-08-31
MXPA02009255A (en) 2003-03-12
IL151392A0 (en) 2003-04-10
GB0007371D0 (en) 2000-05-17
ES2247078T3 (en) 2006-03-01

Similar Documents

Publication Publication Date Title
EP1268445B1 (en) 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases
AU2001239414A1 (en) 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases
US6939872B2 (en) 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors
US6908920B2 (en) Pyrimidine derivatives
US6855719B1 (en) Imidazo[1,2-A]pyridine and pyrazolo[2,3-A]pyridine derivatives
US7745428B2 (en) Imidazo[1,2-A]pyridine having anti-cell-proliferation activity
EP1278735B1 (en) 2,4-di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents
US20090099160A1 (en) 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors
US7427626B2 (en) 2-Anilino-4-(imidazol-5-yl)-pyrimidine derivatives and their use as cdk (cdk2) inhibitors
IL150883A (en) Pyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
ZA200300612B (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation.
US7579344B2 (en) Pyrimidine derivatives possessing cell-cycle inhibitors activity
EP1485375B1 (en) Pyrimidine compounds
EP2044058A1 (en) Chemical compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001239414

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001914026

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 151392

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2399864

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 521032

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002/06957

Country of ref document: ZA

Ref document number: 200206957

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/009255

Country of ref document: MX

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 570630

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 018071570

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 10239790

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1020027012916

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1020027012916

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001914026

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 521032

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 521032

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001239414

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2001914026

Country of ref document: EP